CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
10725409,107254095,5,F,,20220330,20150121,20220406,EXP,,CA-ROCHE-1522668,ROCHE,"Reporter known to Health Authority, Harris M, Larsen G, Montaner JSG Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22(14):1890-2.",44,YR,,M,Y,,,20220406,,MD,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,107254095,HO,,,107254095,11,,,355,DAY,107254095,1,Depression
11465428,1146542810,10,F,,20220429,20150907,20220504,EXP,,CA-ROCHE-1630210,ROCHE,,54,YR,,M,Y,,,20220504,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use;Prescribed overdose,1146542810,DE,,,,,,,,,1146542810,1,Bipolar disorder
12810571,128105714,4,F,,20220518,20161005,20220527,EXP,,CA-APOTEX-2016AP012493,APOTEX,,,,,M,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,128105714,HO,,,,,,,,,128105714,1,Product used for unknown indication
12985056,129850568,8,F,,20220513,20161129,20220525,EXP,,CA-APOTEX-2016AP014805,APOTEX,,52,YR,,M,Y,,,20220525,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,129850568,CA,,,,,,,,,129850568,1,HIV infection
13559360,135593602,2,F,20141121,20220415,20170518,20220419,EXP,,JP-GILEAD-2017-0273052,GILEAD,,43,YR,A,M,Y,,,20220419,,PH,JP,JP,EFAVIRENZ,Beta 2 microglobulin urine increased,135593602,OT,,,135593602,1,20100305,,,,135593602,1,HIV infection
13906408,1390640837,37,F,,20220607,20170825,20220613,EXP,,CA-009507513-0809CAN00001,MERCK,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):1890-2",54,YR,,M,Y,,,20220613,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use;Prescribed overdose,1390640837,HO,,,1390640837,1,20070620,,,,1390640837,1,HIV infection
14165912,141659124,4,F,,20220421,20171107,20220425,EXP,,GB-GILEAD-2017-0303084,GILEAD,,85,YR,E,M,Y,,,20220425,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,141659124,OT,,,141659124,1,,,152,DAY,141659124,1,HIV infection
14248948,142489489,9,F,,20220509,20171204,20220516,EXP,,GB-MYLANLABS-2017M1075159,MYLAN,,85,YR,,M,Y,,,20220516,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,142489489,OT,,,,,,,,,142489489,1,Cardiovascular event prophylaxis
14265678,1426567814,14,F,,20220620,20171208,20220628,EXP,,GB-BAUSCH-BL-2017-032451,BAUSCH AND LOMB,,85,YR,,M,Y,,,20220628,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,1426567814,OT,,,1426567814,5,,,152,DAY,1426567814,1,Crohn's disease
14277495,142774956,6,F,,20220616,20171212,20220627,EXP,,GB-SHIRE-GB201732945,TAKEDA,,85,YR,,M,Y,,,20220627,,CN,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,142774956,OT,,,,,,,,,142774956,1,Inflammatory bowel disease
14462981,144629818,8,F,,20220427,20180130,20220505,EXP,,GB-ALLERGAN-1771124US,ALLERGAN,,,,,M,Y,,,20220505,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,144629818,OT,,,144629818,5,,,152,DAY,144629818,1,Inflammatory bowel disease
14610366,146103663,3,F,20060602,20220418,20180307,20220427,EXP,CA-HEALTH CANADA-E2B_01366855,CA-ALLERGAN-1812285US,ALLERGAN,"Harris M, Larsen G. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22(14):ahead of print",,,,M,Y,,,20220427,,HP,CA,CA,SUSTIVA,Anxiety;Condition aggravated;Contraindicated product administered;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146103663,HO,,,146103663,2,20070729,20060602,355,DAY,146103663,1,Depression
14652614,146526149,9,F,,20220525,20180319,20220531,EXP,,CA-APOTEX-2018AP007741,APOTEX,,44,YR,,M,Y,,,20220531,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,146526149,OT,,,146526149,16,,,355,DAY,146526149,1,Psychotic disorder
14760281,147602812,2,F,,20220513,20180414,20220524,EXP,,GB-MICRO LABS LIMITED-BB2018-00506,MICRO LABS,,85,YR,E,M,Y,,,20220524,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,147602812,OT,,,147602812,4,,,152,DAY,147602812,1,Cardiovascular event prophylaxis
14801460,148014602,2,F,20120101,20220617,20180424,20220622,EXP,,GB-MYLANLABS-2018M1025061,MYLAN,,59,YR,,F,Y,,,20220622,,CN,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Knee operation,148014602,OT,,,,,,,,,148014602,1,HIV infection
15095440,150954408,8,F,20171006,20220527,20180702,20220603,EXP,,GB-GILEAD-2018-0347475,GILEAD,,43,YR,A,F,Y,,,20220603,,CN,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Hepatic cytolysis;Intentional product use issue;Maternal exposure during pregnancy,150954408,OT,,,150954408,1,20171006,20180205,122,DAY,150954408,1,HIV infection
15112110,1511211010,10,F,20171006,20220621,20180705,20220627,EXP,,GB-GILEAD-2018-0347708,GILEAD,,3,MON,I,M,Y,,,20220627,,MD,GB,GB,EFAVIRENZ,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,1511211010,CA,,,1511211010,1,20171006,20180205,122,DAY,1511211010,1,HIV infection
15123625,1512362527,27,F,20180205,20220429,20180710,20220513,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20220513,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362527,OT,,,1512362527,1,20171006,20180205,4,MON,1512362527,1,HIV infection
15123626,1512362621,21,F,20171006,20220509,20180710,20220521,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063878,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220521,,HP,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,1512362621,OT,,,1512362621,1,20171006,,123,DAY,1512362621,1,Product used for unknown indication
15246169,152461693,3,F,20180209,20180731,20180806,20220624,EXP,,LS-VIIV HEALTHCARE LIMITED-LS2018GSK140125,VIIV,,,,,,Y,,,20220624,,MD,LS,LS,EFAVIRENZ,Alanine aminotransferase increased;Altered state of consciousness;Aspartate aminotransferase increased;Dehydration;Dizziness;Feeling drunk;Gamma-glutamyltransferase increased;Hyperlactacidaemia;Hypokalaemia;Hypophagia;Hypotension;Hypothyroidism;Intestinal ischaemia;Metabolic acidosis;Oral herpes;Pneumocystis jirovecii pneumonia;Pulmonary embolism;Syncope;Tremor;Vomiting,152461693,HO,,,152461693,1,20180216,20180715,153,DAY,152461693,1,HIV infection
15249829,152498296,6,F,20060216,20220513,20180807,20220514,EXP,,FR-ABBVIE-18S-056-2444229-00,ABBVIE,,25,YR,,F,Y,56,KG,20220513,,MD,COUNTRY NOT SPECIFIED,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,152498296,HO,,,152498296,1,20050908,20050908,,,152498296,1,HIV infection
15363025,153630259,9,F,20171006,20220616,20180907,20220630,EXP,GB-EMA-DD-20180827-KSEVHUMANWT-125137,GB-NOVOPROD-619421,NOVO NORDISK,,,,,M,Y,,,20220630,,MD,GB,GB,EFAVIRENZ,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153630259,OT,,,153630259,2,20171006,20180205,122,DAY,153630259,1,Foetal exposure during pregnancy
15480679,154806796,6,F,20050813,20220516,20181010,20220524,EXP,,PHHY2009FR075290,NOVARTIS,,25,YR,,F,Y,56,KG,20220524,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Exposure during pregnancy;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,154806796,HO,,,154806796,1,20050513,20050908,119,DAY,154806796,1,HIV infection
15573679,155736799,9,F,,20220421,20181101,20220429,EXP,,CA-TEVA-2018-CA-968128,TEVA,,54,YR,A,M,Y,,,20220429,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Prescribed overdose,155736799,DE,,,,,,,,,155736799,1,HIV infection
15734371,1573437110,10,F,20011001,20210810,20181218,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-A200601823,VIIV,,,,,,Y,,,20220624,,MD,JP,JP,EFAVIRENZ,Arterial stenosis;Hepatic steatosis;Hyperlipidaemia,1573437110,OT,,,1573437110,1,20000706,20030331,998,DAY,1573437110,1,Acquired immunodeficiency syndrome
15734587,1573458710,10,F,20011001,20210810,20181218,20220628,EXP,,JP-GLAXOSMITHKLINE-A200601823,GLAXOSMITHKLINE,,,,,,Y,,,20220628,,MD,JP,JP,EFAVIRENZ,Arterial stenosis;Hepatic steatosis;Hyperlipidaemia,1573458710,OT,,,1573458710,1,20000706,20030331,998,DAY,1573458710,1,Acquired immunodeficiency syndrome
15886086,158860865,5,F,20090618,20220404,20190129,20220406,EXP,,PHHY2018FR195297,NOVARTIS,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). CHEMICAL BIOLOGY AND DRUG DESIGN. 2018;93:13378",47,YR,,M,Y,,,20220407,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,158860865,OT,,,,,,,,,158860865,1,HIV infection
15934516,159345167,7,F,20050813,20220519,20190207,20220525,EXP,,FR-MYLANLABS-2019M1011150,MYLAN,,25,YR,,F,Y,56,KG,20220525,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,159345167,HO,,,159345167,1,20050523,20050908,109,DAY,159345167,1,HIV infection
15934528,159345286,6,F,,20220512,20190207,20220517,EXP,,FR-MYLANLABS-2019M1011151,MYLAN,,26,WK,,F,Y,,,20220517,,MD,FR,FR,EFAVIRENZ,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,159345286,OT,,,159345286,1,20050523,20050908,109,DAY,159345286,1,HIV infection
15983366,159833663,3,F,,20220604,20190220,20220618,EXP,,IT-AUROBINDO-AUR-APL-2019-008587,AUROBINDO,"Cattaneo D, Giacomelli A, Gervasoni C.. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?.. Obesity.. 2018;26 (8):1251-1252",40,YR,,F,Y,,,20220618,,MD,IT,IT,EFAVIRENZ,Drug interaction;Virologic failure,159833663,OT,,,,,,,,,159833663,1,HIV infection
16022512,160225127,7,F,,20220516,20190301,20220530,EXP,,CA-AUROBINDO-AUR-APL-2019-010641,AUROBINDO,,52,YR,,M,Y,,,20220530,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,160225127,CA,,,,,,,,,160225127,1,HIV infection
16051353,160513537,7,F,20110825,20220401,20190308,20220415,EXP,,FR-AUROBINDO-AUR-APL-2018-062564,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T). Chemical biology + drug design. 2019;93(1):50-59",35,YR,,F,Y,,,20220415,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160513537,OT,,,,,,,,,160513537,1,HIV infection
16075222,160752222,2,F,20090618,20220322,20190315,20220405,EXP,,FR-AUROBINDO-AUR-APL-2019-012832,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T).. Chem-Biol-Drug-Des. 2019;93(1):50-59",47,YR,,M,Y,,,20220405,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,160752222,OT,,,,,,,,,160752222,1,HIV infection
16341719,163417192,2,F,20101201,20220602,20190522,20220603,EXP,,PT-ABBVIE-19S-130-2780428-00,ABBVIE,,,,A,F,Y,,,20220603,,MD,PT,PT,EFAVIRENZ,Drug ineffective;Exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163417192,OT,,,163417192,1,201006,201012,,,163417192,1,HIV infection
16360719,163607193,3,F,20100601,20220604,20190528,20220618,EXP,,PT-AUROBINDO-AUR-APL-2019-029299,AUROBINDO,,,,A,F,Y,,,20220618,,MD,PT,PT,EFAVIRENZ,Drug ineffective;Maternal exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,163607193,OT,,,163607193,1,201006,201012,,,163607193,1,HIV infection
16376493,163764932,2,F,20110407,20220322,20190531,20220406,EXP,,FR-AUROBINDO-AUR-APL-2019-031186,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Carlo DD, Romeo I, Artese A, et al.. New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem-Biol-Drug-Des. 2019;93 (1):50-59",51,YR,,F,Y,,,20220406,,HP,FR,FR,EFAVIRENZ,Drug resistance;Treatment failure;Viral mutation identified,163764932,OT,,,,,,,,,163764932,1,HIV infection
16507810,165078103,3,F,20020101,20190624,20190701,20220624,EXP,,DE-VIIV HEALTHCARE LIMITED-DE2019GSK116835,VIIV,,,,,,Y,,,20220624,,MD,DE,DE,EFAVIRENZ;SUSTIVA,Aortic stenosis;Arthralgia;Asthenia;Bronchial carcinoma;Chest pain;Coronary artery disease;Dysphagia;Dyspnoea;Haematuria;Myopathy;Papillary renal cell carcinoma;Stenosis;Systemic scleroderma;Weight decreased,165078103,OT,,,165078103,1,199702,201510,,,165078103,1,HIV infection
16536587,165365877,7,F,20050813,20220518,20190706,20220601,EXP,,FR-AUROBINDO-AUR-APL-2019-038824,AUROBINDO,,26,WK,,F,Y,1.96,KG,20220601,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Anencephaly;Arnold-Chiari malformation;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Foetal malformation;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,165365877,CA,,,165365877,1,20050704,20050908,109,DAY,165365877,1,HIV infection
16542961,165429615,5,F,,20220518,20190709,20220601,EXP,,CA-AUROBINDO-AUR-APL-2019-037761,AUROBINDO,,54,YR,,M,Y,,,20220601,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,165429615,OT,,,,,,,,,165429615,1,Product used for unknown indication
16580930,165809307,7,F,,20200821,20190716,20220624,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2019AMR117290,VIIV,,,,,,Y,,,20220624,,MD,BR,BR,EFAVIRENZ,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint effusion;Joint swelling;Malaise;Neuritis;Neurosyphilis;Oedema peripheral;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal deformity;White blood cell disorder;Wound secretion,165809307,HO,,,165809307,1,201902,,,,165809307,1,HIV infection
16580959,165809597,7,F,,20200821,20190716,20220628,EXP,,BR-GLAXOSMITHKLINE-BR2019AMR117290,GLAXOSMITHKLINE,,,,,,Y,,,20220628,,MD,BR,BR,EFAVIRENZ,Arthritis infective;Back pain;C-reactive protein;CD4 lymphocytes increased;Colitis microscopic;Condition aggravated;Diarrhoea;Gait disturbance;Joint effusion;Joint swelling;Malaise;Neuritis;Neurosyphilis;Oedema peripheral;Pain;Pericardial effusion;Pleural effusion;Psoriatic arthropathy;Rheumatic disorder;Spinal deformity;White blood cell disorder;Wound secretion,165809597,OT,,,165809597,1,201902,,,,165809597,1,HIV infection
16663985,166639852,2,F,,20220614,20190802,20220623,EXP,,IT-MYLANLABS-2019M1032806,MYLAN,"Cattaneo D, Giacomelli A, Gervasoni C.. Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution. Obesity. 2018;26(8):1251-2",39,YR,,F,Y,,,20220623,,MD,IT,IT,EFAVIRENZ,Drug interaction;Virologic failure,166639852,OT,,,,,,,,,166639852,1,HIV infection
16826078,168260783,3,F,,20220517,20190919,20220601,EXP,,CA-AUROBINDO-AUR-APL-2019-059693,AUROBINDO,,44,YR,,M,Y,,,20220601,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,168260783,HO,,,168260783,10,,,355,DAY,168260783,1,Psychotic disorder
16854746,168547463,3,F,20110101,20220526,20190926,20220603,EXP,,US-GILEAD-2019-0429522,GILEAD,,51,YR,A,F,Y,69.841,KG,20220603,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;End stage renal disease;Fatigue;Hyperparathyroidism secondary;Loss of personal independence in daily activities;Nephrogenic anaemia;Pain;Quality of life decreased;Renal failure,168547463,OT,,,168547463,1,201107,20130812,2190,DAY,168547463,1,HIV infection
16884756,168847563,3,F,,20220414,20191004,20220419,EXP,,PT-MYLANLABS-2019M1091779,MYLAN,"Cardoso M, Baptista T,  Diogo I,  Aleixo MJ, Marques N, Mansinho K. et al.. Two cases of dolutegravir failure with R263K mutation. AIDS. 2018;32:2639-2642",29,YR,,F,Y,,,20220419,,HP,PT,PT,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Exposure during pregnancy;Gastrointestinal disorder;Live birth;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,168847563,OT,,,,,,,,,168847563,1,HIV infection
16935237,169352372,2,F,20171006,20220511,20191018,20220517,EXP,,GB-MYLANLABS-2019M1097788,MYLAN,,,,A,F,Y,,,20220517,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,169352372,OT,,,169352372,2,20171006,20180205,123,DAY,169352372,1,Product used for unknown indication
17044956,170449567,7,F,,20220420,20191118,20220427,EXP,,CA-BAUSCH-BL-2019-058588,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1892. doi:10.1097/QAD.0b013e32830e0169",54,YR,,M,Y,,,20220427,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Drug interaction;Psychiatric decompensation,170449567,OT,,,,,,,,,170449567,1,Bipolar disorder
17180948,171809482,2,F,,20220510,20191220,20220523,EXP,,GB-AUROBINDO-AUR-APL-2019-105719,AUROBINDO,,43,YR,,F,Y,,,20220523,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Maternal exposure during pregnancy,171809482,OT,,,,,,,,,171809482,1,Product used for unknown indication
17250665,172506654,4,F,,20220601,20200109,20220608,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020003324,VIIV,,,,,,Y,,,20220608,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,172506654,OT,,,,,,,,,172506654,1,HIV infection
17250675,172506754,4,F,,20220601,20200109,20220608,EXP,,CA-GLAXOSMITHKLINE-CA2020003324,GLAXOSMITHKLINE,,,,,,Y,,,20220608,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,172506754,OT,,,,,,,,,172506754,1,HIV infection
17366674,173666743,3,F,,20201123,20200204,20220624,EXP,,BW-MYLANLABS-2020M1013049,MYLAN,,42,YR,,F,Y,,,20220624,,HP,BW,BW,EFAVIRENZ,Maternal exposure during pregnancy;Stillbirth,173666743,OT,,,,,,,,,173666743,1,HIV infection
17549433,175494335,5,F,,20200801,20200317,20220624,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK046275,VIIV,,,,,,Y,,,20220624,,HP,NG,NG,EFAVIRENZ,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175494335,OT,,,,,,,,,175494335,1,HIV infection
17579467,175794674,4,F,20150101,20220325,20200325,20220520,EXP,,US-GILEAD-2020-0456157,GILEAD,,,,A,M,Y,68.027,KG,20220520,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone density decreased;Decreased activity;Depression;Diarrhoea;Economic problem;Emotional distress;Fatigue;Headache;Left ventricular failure;Osteonecrosis;Osteoporosis;Pain,175794674,OT,,,175794674,1,20100802,20170729,2553,DAY,175794674,1,HIV infection
17697229,176972293,3,F,,20200806,20200423,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2020068351,VIIV,,,,,,Y,,,20220624,,MD,JP,JP,EFAVIRENZ,Surgical vascular shunt,176972293,HO,,,,,,,,,,,
17732671,177326715,5,F,20070101,20220516,20200501,20220527,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020GSK074404,VIIV,,44,YR,,M,Y,,,20220527,,MD,CA,CA,SUSTIVA,Drug interaction;Psychiatric decompensation,177326715,HO,,,177326715,3,20070626,,,,177326715,1,Depression
17732677,177326775,5,F,20070101,20220516,20200501,20220527,EXP,,CA-GLAXOSMITHKLINE-CA2020GSK074404,GLAXOSMITHKLINE,,,,,,Y,,,20220527,,MD,CA,CA,SUSTIVA,Drug interaction;Psychiatric decompensation,177326775,HO,,,177326775,3,20070626,,,,177326775,1,Depression
17902855,179028553,3,F,20050813,20220519,20200616,20220523,EXP,FR-GILEAD-2009-0020445,NVSC2020FR164261,NOVARTIS,,26,WK,,F,Y,1.19,KG,20220523,,MD,FR,FR,EFAVIRENZ;SUSTIVA,Anencephaly;Arnold-Chiari malformation;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Foetal malformation;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,179028553,CA,,,179028553,2,20050704,20050908,109,DAY,179028553,1,Foetal exposure during pregnancy
17910386,179103864,4,F,20110311,20220324,20200618,20220401,EXP,,US-GILEAD-2020-0473224,GILEAD,,47,YR,A,M,Y,53.07,KG,20220401,,LW,US,US,SUSTIVA,Acute kidney injury;Ankle fracture;Chronic kidney disease;Emotional distress;End stage renal disease;Fatigue;Fibula fracture;Foot fracture;Mobility decreased;Multiple fractures;Musculoskeletal disorder;Pain;Renal failure;Tibia fracture,179103864,HO,,,179103864,1,2004,201906,1650,DAY,179103864,1,HIV infection
17911115,179111154,4,F,20190401,20220324,20200618,20220401,EXP,,US-GILEAD-2020-0473488,GILEAD,,55,YR,A,F,Y,106.58,KG,20220401,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Cardiac failure congestive;Chronic kidney disease;Depression;End stage renal disease;Osteoporosis;Renal failure,179111154,DE,,,179111154,1,2007,201801,967,DAY,179111154,1,HIV infection
17912636,179126365,5,F,20080101,20220325,20200618,20220401,EXP,,US-GILEAD-2020-0473465,GILEAD,,47,YR,A,F,Y,72.562,KG,20220401,,LW,US,US,SUSTIVA,Anxiety;Bone density decreased;Bone loss;Chronic kidney disease;Depression;Exostosis;Foot fracture;Gingival swelling;Haematuria;Hand fracture;Intervertebral disc degeneration;Loose tooth;Multiple fractures;Nephrolithiasis;Oropharyngeal plaque;Osteoarthritis;Osteopenia;Osteoporosis;Periodontitis;Renal cyst;Renal failure;Scoliosis;Spinal osteoarthritis;Tooth fracture;Tooth loss;Upper limb fracture;Ureterolithiasis;Vertebral foraminal stenosis,179126365,HO,,,179126365,1,2004,20150924,1554,DAY,179126365,1,HIV infection
17915157,179151575,5,F,20131129,20220420,20200619,20220425,EXP,,US-GILEAD-2020-0473732,GILEAD,,59,YR,A,F,Y,102.04,KG,20220425,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;Fracture;Loss of personal independence in daily activities;Osteonecrosis;Osteopenia;Osteoporosis;Pain,179151575,OT,,,179151575,1,20100204,20151207,2132,DAY,179151575,1,HIV infection
17949727,1794972713,13,F,,20220609,20200626,20220620,EXP,CA-MHPD-E2B_02966351,CA-Accord-186554,ACCORD,,54,YR,,M,Y,,,20220620,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,1794972713,OT,,,,,,,,,1794972713,1,Bipolar disorder
17964921,179649217,7,F,20180604,20220617,20200630,20220623,EXP,,JP-ELI_LILLY_AND_COMPANY-JP202006011785,ELI LILLY AND CO,,56,YR,,M,Y,48.9,KG,20220623,,CN,JP,JP,EFAVIRENZ,Brain natriuretic peptide increased;Hypoxia;Oxygen saturation decreased;Pulmonary arterial hypertension,179649217,DE,,,179649217,2,20180301,20180311,11,DAY,179649217,1,Pulmonary arterial hypertension
17981932,179819325,5,F,20070809,20220502,20200706,20220506,EXP,,US-GILEAD-2020-0475831,GILEAD,,53,YR,A,F,Y,81.633,KG,20220506,,LW,US,US,SUSTIVA,Acute kidney injury;Bone density decreased;Bone loss;Chronic kidney disease;Emotional distress;End stage renal disease;Loss of personal independence in daily activities;Nausea;Osteopenia;Pain;Renal failure;Vomiting,179819325,HO,,,179819325,1,2001,2013,3773,DAY,179819325,1,HIV infection
17985085,1798508511,11,F,,20220424,20200706,20220502,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020EME116192,VIIV,,,,,M,Y,,,20220502,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1798508511,HO,,,,,,,,,1798508511,1,Product used for unknown indication
17985108,1798510811,11,F,,20220424,20200706,20220502,EXP,,GB-GLAXOSMITHKLINE-GB2020EME116192,GLAXOSMITHKLINE,,,,,M,Y,,,20220502,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1798510811,HO,,,,,,,,,1798510811,1,Product used for unknown indication
17990876,1799087622,22,F,,20220615,20200707,20220622,EXP,,GB-MYLANLABS-2020M1060756,MYLAN,,,,,M,Y,,,20220622,,CN,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1799087622,OT,,,,,,,,,1799087622,1,Product used for unknown indication
18002318,1800231817,17,F,,20220512,20200709,20220524,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-053886,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220524,,CN,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1800231817,HO,,,,,,,,,1800231817,1,Product used for unknown indication
18022611,1802261121,21,F,,20220531,20200715,20220614,EXP,,GB-AUROBINDO-AUR-APL-2020-034425,AUROBINDO,,,,,M,Y,,,20220614,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,1802261121,HO,,,,,,,,,1802261121,1,Product used for unknown indication
18117892,181178925,5,F,20110101,20201015,20200806,20220506,EXP,,US-GILEAD-2020-0486848,GILEAD,,,,A,M,Y,,,20220506,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Economic problem;Emotional distress;Pain;Renal failure;Tooth loss,181178925,DE,,,181178925,1,2007,2015,1383,DAY,181178925,1,HIV infection
18179409,181794099,9,F,,20220603,20200821,20220614,EXP,,CA-ROCHE-2583896,ROCHE,,52,YR,,M,Y,,,20220614,,HP,CA,,EFAVIRENZ;SUSTIVA,Blood lactic acid increased;Diplopia;Dysphagia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,181794099,OT,,,,,,,,,181794099,1,HIV infection
18314365,183143652,2,F,,20200915,20200925,20220624,EXP,,AU-VIIV HEALTHCARE LIMITED-AU2020186205,VIIV,,,,,,Y,,,20220624,,MD,AU,AU,EFAVIRENZ,Acute cardiac event;Drug ineffective,183143652,OT,,,,,,,,,183143652,1,Product used for unknown indication
18314375,183143752,2,F,,20200915,20200925,20220627,EXP,,AU-GLAXOSMITHKLINE-AU2020186205,GLAXOSMITHKLINE,,,,,,Y,,,20220627,,MD,AU,AU,EFAVIRENZ,Acute cardiac event;Drug ineffective,183143752,OT,,,,,,,,,183143752,1,Product used for unknown indication
18322906,183229063,3,F,,20220404,20200928,20220415,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-075418,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220415,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction,183229063,HO,,,,,,,,,183229063,1,Product used for unknown indication
18349036,183490366,6,F,,20220601,20201006,20220608,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK189276,GLAXOSMITHKLINE,,,,,,Y,,,20220608,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,183490366,OT,,,,,,,,,183490366,1,HIV infection
18544053,185440533,3,F,,20220613,20201124,20220617,EXP,,CA-JNJFOC-20201125727,JOHNSON AND JOHNSON,,44,YR,A,M,Y,,,20220617,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,185440533,HO,,,,,,,,,185440533,1,Depression
18553691,185536914,4,F,20130725,20220406,20201127,20220408,EXP,,US-GILEAD-2020-0505720,GILEAD,,54,YR,A,F,Y,,,20220408,,LW,US,US,SUSTIVA,Anaemia;Blood creatinine increased;Bone density decreased;Chronic kidney disease;Chronic kidney disease-mineral and bone disorder;Emotional distress;End stage renal disease;Glomerular filtration rate increased;Loss of personal independence in daily activities;Muscular weakness;Pain;Protein total abnormal;Protein total increased;Renal failure;Tooth loss,185536914,OT,,,185536914,1,20090701,20111106,858,DAY,185536914,1,HIV infection
18605497,186054972,2,F,20050913,20201207,20201211,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-A200603214,VIIV,,,,,,Y,,,20220624,,MD,JP,JP,EFAVIRENZ,Asthma;Death;Suicide attempt,186054972,DE,,,186054972,1,20050113,,,,186054972,1,HIV infection
18605554,186055542,2,F,20050913,20201207,20201211,20220628,EXP,,JP-GlaxoSmithKline-B0434971A,GLAXOSMITHKLINE,,,,,,Y,,,20220628,,MD,JP,JP,EFAVIRENZ,Asthma;Death;Suicide attempt,186055542,HO,,,186055542,1,20050113,,,,186055542,1,HIV infection
18658805,186588054,4,F,20160415,20220521,20201224,20220526,EXP,,US-GILEAD-2020-0509256,GILEAD,,40,YR,A,M,Y,72.575,KG,20220526,,LW,US,US,SUSTIVA,Bone loss;Emotional distress;Loss of personal independence in daily activities;Osteonecrosis;Pain;Skeletal injury,186588054,OT,,,186588054,1,20101201,20130831,1004,DAY,186588054,1,HIV infection
18663452,186634523,3,F,20181001,20220324,20201224,20220401,EXP,,US-009507513-2012USA011140,MERCK,,,,,F,Y,,,20220401,,LW,US,US,SUSTIVA,Ankle fracture;Bone density decreased;Bone loss;Multiple fractures;Osteonecrosis;Osteoporosis;Renal injury;Skeletal injury,186634523,OT,,,186634523,1,20101231,20110520,141,DAY,186634523,1,HIV infection
18703934,187039343,3,F,20181001,20220331,20210106,20220413,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-111175,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20220413,,LW,US,US,SUSTIVA,Ankle fracture;Bone density decreased;Bone loss;Multiple fractures;Osteoporosis;Renal injury;Skeletal injury,187039343,OT,,,187039343,2,2004,2017,15,YR,187039343,1,HIV infection
18739723,187397232,2,F,20050401,20210108,20210114,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN003775,VIIV,,,,,,Y,,,20220624,,MD,JP,JP,EFAVIRENZ,Blood lactate dehydrogenase increased;Diabetes mellitus;Dyslipidaemia;Renal impairment,187397232,OT,,,187397232,1,201302,,,,187397232,1,HIV infection
18867761,188677613,3,F,,20210211,20210209,20220624,EXP,,FR-VIIV HEALTHCARE LIMITED-FR2021GSK033741,VIIV,,,,,,Y,,,20220624,,HP,FR,FR,EFAVIRENZ,Foetal exposure during pregnancy;Polycystic liver disease;Sickle cell disease;Spleen malformation,188677613,CA,,,188677613,1,20060426,20061018,130,DAY,188677613,1,HIV infection
18870387,188703878,8,F,20210101,20220530,20210209,20220603,EXP,,CN-GILEAD-2021-0515844,GILEAD,,,,A,M,Y,62,KG,20220603,,HP,CN,CN,TENOFOVIR DISOPROXIL FUMARATE/LAMIVUDINE/EFAVIRENZ,Liver injury,188703878,HO,,,188703878,1,20201229,20210112,14,DAY,188703878,1,HIV infection
18916042,189160422,2,F,,20220412,20210218,20220414,EXP,,AU-JNJFOC-20210220797,JOHNSON AND JOHNSON,,,,,,Y,,,20220414,,HP,AU,AU,EFAVIRENZ,Dyslipidaemia,189160422,OT,,,,,,,,,189160422,1,HIV infection
18924449,189244495,5,F,,20220404,20210222,20220606,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-013816,BRISTOL MYERS SQUIBB,,44,YR,A,M,Y,,,20220606,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,189244495,HO,,,189244495,2,,,355,DAY,189244495,1,HIV infection
18930080,189300802,2,F,20070101,20220525,20210223,20220527,EXP,,CA-BAUSCH-BL-2021-005979,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1891. doi:10.1097/QAD.0b013e32830e0169",44,YR,,M,Y,,,20220527,,MD,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,189300802,HO,,,189300802,5,20070626,20070522,355,DAY,189300802,1,Depression
18930097,189300973,3,F,,20220520,20210223,20220524,EXP,,CA-BAUSCH-BL-2021-005985,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220524,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189300973,OT,,,,,,,,,189300973,1,Bipolar disorder
18931021,189310212,2,F,,20220610,20210223,20220622,EXP,,CA-BAUSCH-BL-2021-005965,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220622,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189310212,OT,,,,,,,,,189310212,1,Bipolar disorder
18947860,189478603,3,F,,20220525,20210226,20220601,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053471,GLAXOSMITHKLINE,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-1891",,,,,Y,,,20220601,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,189478603,HO,,,,,,,,,189478603,1,Depression
18958430,189584305,5,F,,20220520,20210302,20220527,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053512,VIIV,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189584305,OT,,,,,,,,,189584305,1,Bipolar disorder
18958433,189584335,5,F,,20220520,20210302,20220527,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053512,GLAXOSMITHKLINE,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,189584335,OT,,,,,,,,,189584335,1,Bipolar disorder
18962597,189625974,4,F,,20220520,20210303,20220527,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK053501,VIIV,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189625974,OT,,,,,,,,,189625974,1,Bipolar disorder
18962619,189626194,4,F,,20220520,20210303,20220527,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK053501,GLAXOSMITHKLINE,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,189626194,OT,,,,,,,,,189626194,1,Bipolar disorder
19081584,190815847,7,F,20060602,20220428,20210331,20220506,EXP,,CA-AstraZeneca-2020SF04539,ASTRAZENECA,,44,YR,,M,Y,,,20220506,,MD,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,190815847,OT,,,190815847,1,20070729,20070730,2,DAY,190815847,1,Depression
19153791,191537914,4,F,,20220520,20210419,20220527,EXP,,CA-GLAXOSMITHKLINE-CA2021GSK079633,GLAXOSMITHKLINE,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,191537914,DE,,,,,,,,,191537914,1,Bipolar disorder
19153924,191539244,4,F,,20220520,20210419,20220527,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2021GSK079633,VIIV,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,191539244,DE,,,,,,,,,191539244,1,Bipolar disorder
19169020,191690202,2,F,,20220524,20210422,20220603,EXP,,CA-TEVA-2021-CA-1901914,TEVA,,44,YR,A,M,Y,,,20220603,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,191690202,OT,,,,,,,,,191690202,1,HIV infection
19178397,191783973,3,F,20210201,20210513,20210426,20220604,EXP,,GB-AUROBINDO-AUR-APL-2021-016585,AUROBINDO,,,,A,F,Y,,,20220604,,HP,GB,GB,EFAVIRENZ,COVID-19;Product dose omission issue;Product use issue;Pruritus;Skin disorder;Skin irritation;Skin ulcer,191783973,OT,,,,,,,,,191783973,1,Product used for unknown indication
19433699,194336992,2,F,20160501,20220518,20210617,20220523,PER,,US-GILEAD-2021-0536633,GILEAD,,59,YR,A,M,Y,77.11,KG,20220523,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Pollakiuria;Renal failure;Renal impairment,194336992,OT,,,194336992,1,2012,201605,,,194336992,1,HIV infection
19455856,194558563,3,F,20060101,20220426,20210624,20220429,PER,,US-GILEAD-2021-0537460,GILEAD,,,,A,F,Y,60.317,KG,20220429,,LW,US,US,SUSTIVA,Abdominal pain lower;Anaemia;Anhedonia;Anxiety;Arthralgia;Back pain;Bone density decreased;Bone pain;Emotional distress;End stage renal disease;Fatigue;Osteopenia;Pain;Proteinuria;Renal failure;Renal pain;Urinary incontinence,194558563,HO,,,194558563,1,2004,201407,,,194558563,1,HIV infection
19455918,194559182,2,F,20160401,20220606,20210624,20220609,EXP,,US-GILEAD-2021-0537601,GILEAD,,44,YR,A,M,Y,90.703,KG,20220609,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Osteoporosis;Pain,194559182,OT,,,194559182,1,2009,2020,,,194559182,1,HIV infection
19469274,194692742,2,F,20130101,20220422,20210628,20220501,EXP,,US-GILEAD-2021-0537598,GILEAD,,53,YR,A,M,Y,78.005,KG,20220501,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Nephropathy;Osteoporosis;Pain,194692742,OT,,,194692742,1,2007,2018,,,194692742,1,HIV infection
19608298,196082982,2,F,,20220622,20210726,20220628,EXP,,CA-BAUSCH-BL-2021-025922,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220628,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,196082982,OT,,,,,,,,,196082982,1,Product used for unknown indication
19701796,197017962,2,F,,20220620,20210813,20220623,EXP,,CA-ROCHE-2884622,ROCHE,,54,YR,,M,Y,,,20220623,,HP,CA,,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197017962,OT,,,,,,,,,197017962,1,Bipolar disorder
19702158,197021582,2,F,,20220429,20210813,20220505,EXP,,CA-ROCHE-2885595,ROCHE,,54,YR,,M,Y,,,20220505,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities;Off label use,197021582,OT,,,,,,,,,197021582,1,Bipolar disorder
19748412,197484122,2,F,,20220330,20210826,20220406,EXP,,CA-ROCHE-2898001,ROCHE,,54,YR,,M,Y,,,20220406,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,197484122,OT,,,,,,,,,197484122,1,Bipolar disorder
19752645,197526453,3,F,,20220602,20210827,20220607,EXP,,CA-ROCHE-2899547,ROCHE,,54,YR,,M,Y,,,20220607,,HP,CA,,SUSTIVA,Depression;Drug interaction,197526453,DE,,,,,,,,,197526453,1,Bipolar disorder
19793324,197933242,2,F,20140101,20220429,20210906,20220512,EXP,,US-GILEAD-2021-0547306,GILEAD,,,,A,M,Y,78.458,KG,20220512,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;Fanconi syndrome acquired;Fatigue;Pain;Protein urine present;Proteinuria;Renal impairment,197933242,OT,,,197933242,1,2006,201410,,,197933242,1,HIV infection
19800129,198001292,2,F,20160101,20220516,20210908,20220520,PER,,US-GILEAD-2021-0547348,GILEAD,,,,A,M,Y,98.413,KG,20220520,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Emotional distress;Gait disturbance;Osteopenia;Pain;Renal disorder;Somnolence,,,,,198001292,1,2015,201505,,,198001292,1,HIV infection
19800836,198008362,2,F,20170601,20220519,20210908,20211227,EXP,,US-GILEAD-2021-0547363,GILEAD,,59,YR,A,M,Y,83.9,KG,20220525,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Muscle spasms;Nocturia;Pain;Renal disorder;Renal impairment;Renal injury;Renal pain,198008362,OT,,,198008362,1,2006,201612,,,198008362,1,HIV infection
19806698,198066982,2,F,,20220523,20210909,20220524,EXP,,US-GILEAD-2021-0547384,GILEAD,,,,A,F,Y,70.295,KG,20220524,,LW,US,US,EFAVIRENZ;SUSTIVA,Anhedonia;Anxiety;Arthritis;Back pain;Bone density decreased;Emotional distress;Osteopenia;Osteoporosis;Pain,198066982,OT,,,198066982,1,2003,201601,,,198066982,1,HIV infection
19812616,198126162,2,F,20170101,20220429,20210910,20220504,EXP,,US-GILEAD-2021-0547373,GILEAD,,,,A,M,Y,,,20220504,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Depression;Emotional distress;Femur fracture;Hypertension;Pain;Renal impairment;Renal injury,198126162,OT,,,198126162,1,2005,202002,,,198126162,1,HIV infection
19812823,198128232,2,F,,20210907,20210910,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN190174,VIIV,,,,,,Y,,,20220624,,MD,JP,JP,EFAVIRENZ,Blood HIV RNA increased,198128232,OT,,,,,,,,,198128232,1,HIV infection
19815866,198158662,2,F,20150401,20220425,20210909,20220429,EXP,,US-GILEAD-2021-0547470,GILEAD,,50,YR,A,M,Y,77.098,KG,20220429,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Bone density decreased;Depression;Emotional distress;Gait disturbance;Hip fracture;Mobility decreased;Musculoskeletal pain;Osteopenia;Pain,198158662,OT,,,198158662,1,201501,201709,,,198158662,1,HIV infection
19816298,198162982,2,F,20190101,20220527,20210910,20220603,EXP,,US-GILEAD-2021-0547340,GILEAD,,,,A,F,Y,45.351,KG,20220603,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Depression;Dysstasia;Emotional distress;Gait disturbance;Impaired work ability;Insomnia;Mobility decreased;Multiple fractures;Osteoporosis;Pain;Rib fracture,198162982,OT,,,198162982,1,2011,201308,,,198162982,1,HIV infection
19816999,198169992,2,F,20161219,20220519,20210910,20220524,EXP,,US-GILEAD-2021-0547354,GILEAD,,58,YR,A,F,Y,57.15,KG,20220524,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Emotional distress;Fracture;Hip fracture;Osteoporosis;Pain,198169992,OT,,,198169992,1,2006,2016,,,198169992,1,HIV infection
19818913,198189132,2,F,20170101,20220613,20210912,20220615,EXP,,US-GILEAD-2021-0547360,GILEAD,,,,A,F,Y,78.912,KG,20220615,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Exercise tolerance decreased;Gait disturbance;Mobility decreased;Pain,198189132,OT,,,198189132,1,2009,2019,,,198189132,1,HIV infection
19845099,198450992,2,F,,20210910,20210916,20220405,EXP,,ZA-GILEAD-2021-0548801,GILEAD,"Manickchund N, du Plessis C, John MA, Manzini TC, Moosa M-YS. A case series of emtricitabine-induced pure red cell aplasia. unk. 2021;22(1):1-4. doi:10.4102/sajhivmed.v22i1.1271",37,YR,A,F,Y,,,20220405,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Aplasia pure red cell,198450992,HO,,,,,,,,,198450992,1,HIV infection
19895097,198950972,2,F,,20210927,20210929,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2021JPN202612,VIIV,,,,,,Y,,,20220624,,MD,JP,JP,EFAVIRENZ,Diarrhoea;Renal cancer;Renal impairment,198950972,OT,,,,,,,,,198950972,1,HIV infection
19903750,199037503,3,F,,20220518,20211001,20220527,EXP,,CA-APOTEX-2021AP043245,APOTEX,,54,YR,,M,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,199037503,OT,,,,,,,,,199037503,1,HIV infection
19903764,199037642,2,F,,20220510,20211001,20220520,EXP,,IN-CIPLA LTD.-2021IN06420,CIPLA,"Soneja M, Gupta N, Aggarwal A, Kodan P. Human immunodeficiency virus infection with multiple opportunistic infections: lessons learnt from a non-adherent patient. Oxford Medical Case Reports. 2021;3:79 to 81",,,,,Y,,,20220520,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Cachexia;Dehydration;Depression;Diarrhoea;Dysphagia;Electrolyte imbalance;Ichthyosis;Oral candidiasis;Treatment failure;Treatment noncompliance,199037642,HO,,,,,,,,,199037642,1,Antiretroviral therapy
19945467,199454672,2,F,,20220404,20211012,20220407,EXP,,LV-MYLANLABS-2021M1070855,MYLAN,,41,YR,,M,Y,,,20220407,,MD,LV,LV,EFAVIRENZ,Dizziness;Hyperlipidaemia;Nightmare;Pulmonary hypertension,199454672,OT,,,199454672,1,2018,2020,,,199454672,1,HIV infection
19947437,199474373,3,F,20060705,20220427,20211012,20220504,EXP,,US-GILEAD-2021-0551913,GILEAD,,37,YR,A,M,Y,92.517,KG,20220503,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Blood creatinine increased;Cholelithiasis;Chronic kidney disease;Emotional distress;Pain;Renal failure;Renal impairment,199474373,OT,,,199474373,1,200608,200905,,,199474373,1,HIV infection
19947474,199474743,3,F,20160401,20220531,20211012,20220603,EXP,,US-GILEAD-2021-0551967,GILEAD,,50,YR,A,M,Y,82.553,KG,20220603,,LW,US,US,SUSTIVA,Abdominal discomfort;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;Fatigue;Libido decreased;Loss of personal independence in daily activities;Nausea;Pain;Renal impairment,199474743,OT,,,199474743,1,2001,2004,,,199474743,1,HIV infection
19977951,199779515,5,F,20210101,20220420,20211020,20220422,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2021EME212973,VIIV,"Bowman C, Ambrose A, Simoes P, Florman K, Kanitkar T, Katiyar A et al.. Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV",,,,M,Y,,,20220422,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199779515,OT,,,199779515,1,20191114,201911,,,199779515,1,HIV infection
19978643,199786435,5,F,20210101,20220420,20211020,20220422,EXP,,GB-GLAXOSMITHKLINE-GB2021EME212973,GLAXOSMITHKLINE,"Bowman C, Ambrose A, Simoes P, Florman K, Kanitkar T, Katiyar A et al.. Performance of dolutegravir based two drug regimens (DTG-2DR) in a large real-world cohort of people with HIV",,,,M,Y,,,20220422,,MD,GB,GB,EFAVIRENZ,Drug ineffective;Pathogen resistance;Product administration error;Treatment noncompliance;Viral mutation identified;Virologic failure,199786435,OT,,,199786435,1,20191114,201911,,,199786435,1,HIV infection
20046628,200466282,2,F,20141001,20220519,20211109,20220524,EXP,,US-GILEAD-2021-0555234,GILEAD,,56,YR,A,F,Y,73.923,KG,20220524,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Discomfort;Emotional distress;Gait disturbance;Osteoporosis;Pain;Pain in extremity;Quality of life decreased,200466282,OT,,,200466282,1,200412,201601,,,200466282,1,HIV infection
20049732,200497322,2,F,20040101,20220601,20211109,20220603,EXP,,US-GILEAD-2021-0555302,GILEAD,,,,A,F,Y,81.646,KG,20220602,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Asthenia;Bone demineralisation;Chronic kidney disease;Emotional distress;Muscular weakness;Osteopenia;Osteoporosis;Pain;Renal failure,200497322,OT,,,200497322,1,2004,201801,,,200497322,1,HIV infection
20057137,200571373,3,F,20020605,20211220,20211111,20220628,EXP,,JP-GLAXOSMITHKLINE-A20032850,GLAXOSMITHKLINE,,,,,,Y,,,20220628,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571373,HO,,,200571373,1,20010627,20030331,642,DAY,200571373,1,Acquired immunodeficiency syndrome
20057140,200571403,3,F,20020605,20211220,20211111,20220624,EXP,,JP-VIIV HEALTHCARE LIMITED-A20032850,VIIV,,,,,,Y,,,20220624,,MD,JP,JP,EFAVIRENZ,Blood uric acid increased;Cataract;Gastrooesophageal reflux disease;Hyperlipidaemia;Hypertension;Hyperuricaemia;Lipoatrophy;Otitis media,200571403,HO,,,200571403,1,20010627,20030331,642,DAY,200571403,1,Acquired immunodeficiency syndrome
20113979,201139792,2,F,20120101,20220520,20211125,20220525,EXP,,US-GILEAD-2021-0557438,GILEAD,,,,A,F,Y,68.481,KG,20220525,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Chronic kidney disease;Dysstasia;Emotional distress;Loss of personal independence in daily activities;Mobility decreased;Osteoporosis;Pain,201139792,OT,,,201139792,1,2001,2004,,,201139792,1,HIV infection
20118774,201187742,2,F,20100401,20220418,20211126,20220422,EXP,,US-GILEAD-2021-0557192,GILEAD,,51,YR,A,M,Y,,,20220421,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Emotional distress;End stage renal disease;Fatigue;Loss of personal independence in daily activities;Mobility decreased;Pain;Renal failure,201187742,OT,,,201187742,1,2004,200701,,,201187742,1,HIV infection
20120093,201200932,2,F,20060801,20220509,20211126,20220516,EXP,,US-GILEAD-2021-0557450,GILEAD,,45,YR,A,M,Y,79.365,KG,20220515,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Emotional distress;Gait disturbance;Loss of personal independence in daily activities;Micturition disorder;Mobility decreased;Osteopenia;Osteoporosis;Pain;Proteinuria;Rash,201200932,OT,,,201200932,1,200310,200401,,,201200932,1,HIV infection
20123708,201237082,2,F,20130601,20220513,20211129,20220516,EXP,,US-GILEAD-2021-0557125,GILEAD,,52,YR,A,M,Y,120.18,KG,20220516,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Chronic kidney disease;Emotional distress;Gait disturbance;Pain,201237082,OT,,,201237082,1,2004,2007,,,201237082,1,HIV infection
20124059,201240592,2,F,20160401,20220531,20211129,20220603,EXP,,US-GILEAD-2021-0557458,GILEAD,,50,YR,A,M,Y,76.644,KG,20220603,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Asthenia;Bone demineralisation;Emotional distress;Fatigue;Foot fracture;Loss of personal independence in daily activities;Osteoporosis;Pain,201240592,OT,,,201240592,1,2013,201703,,,201240592,1,HIV infection
20125712,201257122,2,F,20160901,20220425,20211129,20220429,EXP,,US-GILEAD-2021-0557401,GILEAD,,52,YR,A,M,Y,136.05,KG,20220428,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Blood creatinine increased;Chronic kidney disease;Dysstasia;Emotional distress;Loss of personal independence in daily activities;Pain;Renal failure,201257122,OT,,,201257122,1,2005,2017,,,201257122,1,HIV infection
20125879,201258794,4,F,,20220608,20211129,20220616,EXP,,UG-MYLANLABS-2021M1086327,MYLAN,,,,,F,Y,3.4,KG,20220616,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Congenital umbilical hernia;Foetal exposure during pregnancy,201258794,OT,,,201258794,1,20210204,20210203,1032,DAY,201258794,1,HIV infection
20132704,201327042,2,F,20070901,20220519,20211130,20220524,EXP,,US-GILEAD-2021-0557347,GILEAD,,43,YR,A,M,Y,54.422,KG,20220524,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone density decreased;Emotional distress;Foot fracture;Gait disturbance;Multiple fractures;Osteopenia;Osteoporosis;Pain;Pelvic fracture,201327042,OT,,,201327042,1,200510,201706,,,201327042,1,HIV infection
20149844,201498442,2,F,20100901,20220601,20211206,20220606,EXP,,US-GILEAD-2021-0557165,GILEAD,,61,YR,T,M,Y,82.086,KG,20220606,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Dysuria;Emotional distress;Glomerulonephritis;Pain;Pollakiuria,201498442,OT,,,201498442,1,2001,2004,,,201498442,1,HIV infection
20151279,201512792,2,F,20150513,20220401,20211206,20220407,PER,,US-GILEAD-2021-0557334,GILEAD,,52,YR,A,M,Y,57,KG,20220407,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Asthenia;Bone demineralisation;Emotional distress;Muscular weakness;Osteopenia;Pain;Weight decreased;Wrist fracture,,,,,201512792,1,2011,201712,,,201512792,1,HIV infection
20152924,201529243,3,F,20180101,20220602,20211206,20220607,EXP,,US-GILEAD-2021-0557543,GILEAD,,54,YR,A,M,Y,99.773,KG,20220607,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Apathy;Chronic kidney disease;Drug ineffective;Emotional distress;Insomnia;Pain,201529243,OT,,,201529243,1,2003,200501,,,201529243,1,HIV infection
20155343,201553432,2,F,20150901,20220526,20211207,20220603,EXP,,US-GILEAD-2021-0557188,GILEAD,,55,YR,A,M,Y,106.12,KG,20220603,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Nocturia;Pain;Renal impairment,201553432,OT,,,201553432,1,201106,201606,,,201553432,1,HIV infection
20159148,201591482,2,F,20160101,20220602,20211208,20220606,EXP,,US-GILEAD-2021-0557366,GILEAD,,,,A,M,Y,58.05,KG,20220606,,LW,US,US,SUSTIVA,Anaemia;Anhedonia;Anxiety;Asthenia;Chronic kidney disease;Emotional distress;End stage renal disease;Hypertension;Pain;Weight decreased,201591482,OT,,,201591482,1,2006,2011,,,201591482,1,HIV infection
20161207,201612072,2,F,20180101,20220506,20211208,20220512,PER,,US-GILEAD-2021-0557433,GILEAD,,,,,M,Y,97.506,KG,20220512,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Depression;Dysstasia;Emotional distress;Gait disturbance;General physical health deterioration;Mobility decreased;Pain,,,,,201612072,1,2005,201306,,,201612072,1,HIV infection
20162635,201626352,2,F,20130401,20220519,20211208,20220524,PER,,US-GILEAD-2021-0557221,GILEAD,,54,YR,A,F,Y,64.853,KG,20220523,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Depression;Emotional distress;Loss of personal independence in daily activities;Mobility decreased;Nausea;Osteopenia;Pain;Skeletal injury;Vomiting,,,,,201626352,1,2004,201908,,,201626352,1,HIV infection
20167539,201675393,3,F,20120901,20220407,20211209,20220412,EXP,,US-GILEAD-2021-0557448,GILEAD,,56,YR,A,M,Y,63.946,KG,20220412,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Blood test abnormal;Chronic kidney disease;Decreased activity;Emotional distress;Fanconi syndrome acquired;Pain,201675393,OT,,,201675393,1,20050308,201209,,,201675393,1,HIV infection
20168228,201682282,2,F,20080601,20220415,20211210,20220419,EXP,,US-GILEAD-2021-0557471,GILEAD,,25,YR,A,M,Y,77.098,KG,20220419,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Emotional distress;Fatigue;General physical health deterioration;Medical diet;Pain;Renal failure,201682282,HO,,,201682282,1,2007,201607,,,201682282,1,HIV infection
20171241,201712412,2,F,20191001,20220426,20211210,20220429,EXP,,US-GILEAD-2021-0557489,GILEAD,,57,YR,A,F,Y,35.374,KG,20220429,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone pain;Emotional distress;Foot fracture;Hand fracture;Liver disorder;Loss of personal independence in daily activities;Multiple fractures;Osteoporosis;Pain;Renal disorder;Skeletal injury;Spinal fracture,201712412,OT,,,201712412,1,2011,2018,,,201712412,1,HIV infection
20217592,202175927,7,F,20211120,20220516,20211222,20220523,EXP,,DE-TAKEDA-2021TUS079245,TAKEDA,,,,E,M,Y,,,20220523,,HP,DE,DE,EFAVIRENZ,C-reactive protein increased;Femur fracture,202175927,HO,,,202175927,1,20060214,20190106,4710,DAY,202175927,1,Factor VIII deficiency
20220620,202206202,2,F,20100101,20220610,20211223,20220616,EXP,,US-GILEAD-2021-0561983,GILEAD,,,,A,M,Y,61.224,KG,20220616,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone demineralisation;Bone density decreased;Degenerative bone disease;Emotional distress;Fracture;Hip fracture;Multiple fractures;Musculoskeletal procedural complication;Osteopenia;Osteoporosis;Pain;Upper limb fracture,202206202,OT,,,202206202,1,2006,2014,,,202206202,1,HIV infection
20296649,202966492,2,F,20060101,20220325,20220105,20220401,EXP,,US-GILEAD-2022-0563759,GILEAD,,,,A,M,Y,106.12,KG,20220401,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Emotional distress;Pain,202966492,OT,,,202966492,1,2006,201707,,,202966492,1,HIV infection
20302480,203024802,2,F,20181001,20220523,20220106,20220527,EXP,,US-GILEAD-2022-0563753,GILEAD,,57,YR,A,F,Y,63.492,KG,20220526,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthralgia;Back pain;Bone demineralisation;Bone density decreased;Emotional distress;Intervertebral disc degeneration;Mobility decreased;Osteopenia;Osteoporosis;Pain,203024802,OT,,,203024802,1,2012,201811,,,203024802,1,HIV infection
20303394,203033942,2,F,20170101,20220504,20220106,20220506,EXP,,US-GILEAD-2022-0563765,GILEAD,,45,YR,A,F,Y,88.904,KG,20220506,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Arthralgia;Chronic kidney disease;Depression;Emotional distress;Femur fracture;Gait disturbance;Loss of personal independence in daily activities;Mobility decreased;Nausea;Osteoporosis;Pain;Renal failure,203033942,OT,,,203033942,1,2009,201902,,,203033942,1,HIV infection
20310617,203106172,2,F,,20220603,20220107,20220606,EXP,,CA-ABBVIE-22K-028-4223963-00,ABBVIE,,54,YR,,M,Y,,,20220606,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,203106172,DE,,,,,,,,,203106172,1,Bipolar disorder
20332734,203327342,2,F,,20220606,20220113,20220620,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-003921,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220620,,HP,CA,CA,SUSTIVA,Death,203327342,OT,,,,,,,,,203327342,1,Bipolar disorder
20346383,203463832,2,F,20211121,20220602,20220118,20220607,EXP,,ZA-MYLANLABS-2022M1003728,MYLAN,,27,YR,,F,Y,,,20220607,,CN,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,203463832,OT,,,203463832,1,20161116,20211020,1800,DAY,203463832,1,HIV infection
20432545,204325453,3,F,20180508,20220427,20220204,20220504,EXP,,TR-GILEAD-2022-0568528,GILEAD,,56,YR,A,M,Y,70,KG,20220504,,MD,TR,TR,EFAVIRENZ,Genotype drug resistance test positive;Osteonecrosis;Osteopenia;Osteoporosis,204325453,OT,,,204325453,1,2012,,,,204325453,1,HIV infection
20445893,204458932,2,F,20200201,20220602,20220208,20220609,PER,,US-GILEAD-2022-0568978,GILEAD,,54,YR,A,F,Y,86.168,KG,20220609,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Back pain;Bone density decreased;Depression;Emotional distress;Mobility decreased;Osteopenia;Pain,,,,,204458932,1,2006,201910,,,204458932,1,HIV infection
20453658,204536583,3,F,,20220329,20220210,20220408,EXP,,GB-JNJFOC-20220209540,JOHNSON AND JOHNSON,,,,,,Y,,,20220408,,HP,GB,GB,EFAVIRENZ,Treatment failure,204536583,OT,,,,,,,,,204536583,1,HIV infection
20461565,204615652,2,F,,20220607,20220211,20220610,EXP,,CA-AstraZeneca-2022A063503,ASTRAZENECA,,54,YR,,M,Y,,,20220610,,MD,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,204615652,OT,,,,,,,,,204615652,1,Bipolar disorder
20479608,204796082,2,F,20190101,20220715,20220216,20220214,PER,,US-GILEAD-2022-0569302,GILEAD,,,,A,M,Y,325,KG,20220719,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Emotional distress;Pain;Proteinuria;Renal impairment,204796082,OT,,,204796082,1,2007,2019,,,204796082,1,HIV infection
20494870,204948702,2,F,,20220527,20220221,20220531,EXP,,CA-ROCHE-3026280,ROCHE,,54,YR,,M,Y,,,20220531,,HP,CA,,SUSTIVA,Depression;Drug interaction,204948702,OT,,,,,,,,,204948702,1,Bipolar disorder
20497154,204971543,3,F,,20220329,20220221,20220406,EXP,,IN-BAYER-2022A024104,BAYER,Kachhwaha A; Rohila AK; Tripathi S; Meena DS; Khichar S; Kumar D. Acute Myocardial Infarction in Hemophilia A with HIV and Hyperhomocysteinemia- a rare case report. Cardiovascular + hematological disorders drug targets. 2022;XXX:XXX,42,YR,A,M,Y,,,20220406,,HP,IN,IN,EFAVIRENZ,Acute myocardial infarction;Chest pain,204971543,HO,,,204971543,1,2010,,,,204971543,1,Factor VIII deficiency
20516396,205163969,9,F,,20220624,20220225,20220629,EXP,,GB-ORGANON-1711GBR010764,ORGANON,,85,YR,,M,Y,,,20220629,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,205163969,OT,,,205163969,4,,,152,DAY,205163969,1,Cardiovascular event prophylaxis
20522073,205220735,5,F,,20220607,20220226,20220613,EXP,,CA-009507513-2202CAN006974,MERCK,,54,YR,,M,Y,,,20220613,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose;Product use in unapproved indication,205220735,DE,,,,,,,,,205220735,1,HIV infection
20649836,206498362,2,F,20110825,20220330,20220329,20220405,EXP,,FR-JNJFOC-20191209473,JOHNSON AND JOHNSON,,35,YR,A,F,Y,,,20220406,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,206498362,OT,,,,,,,,,206498362,1,HIV infection
20653786,206537864,4,F,,20220601,20220330,20220608,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK056083,VIIV,,,,,,Y,,,20220608,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,206537864,DE,,,,,,,,,206537864,1,Bipolar disorder
20653790,206537904,4,F,,20220601,20220330,20220608,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK056083,GLAXOSMITHKLINE,,,,,,Y,,,20220608,,MD,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,206537904,DE,,,,,,,,,206537904,1,Bipolar disorder
20661241,206612411,1,I,20090618,20220318,20220401,20220401,EXP,,FR-AUROBINDO-AUR-APL-2022-010714,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design. 2018",47,YR,,M,Y,,,20220401,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,206612411,OT,,,,,,,,,206612411,1,HIV infection
20662386,206623862,2,F,20220121,20220617,20220401,20220623,EXP,,FR-AUROBINDO-AUR-APL-2022-007807,AUROBINDO,,,,A,M,Y,92,KG,20220623,,HP,FR,FR,EFAVIRENZ,Disease recurrence;Drug interaction;Hepatitis C,206623862,OT,,,206623862,2,20210528,20210820,84,DAY,206623862,1,HIV infection
20665752,206657521,1,I,20220121,20220318,20220402,20220402,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2022-034348,BRISTOL MYERS SQUIBB,,,,A,M,Y,92,KG,20220402,,HP,FR,FR,EFAVIRENZ,Drug interaction;Hepatitis C,206657521,OT,,,206657521,2,20210528,20210820,12,WK,206657521,1,HIV infection
20667205,206672051,1,I,,20220330,20220404,20220404,EXP,,CA-ABBVIE-21K-028-4111198-00,ABBVIE,,54,YR,,M,Y,,,20220404,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction,206672051,OT,,,,,,,,,206672051,1,Product used for unknown indication
20669823,206698232,2,F,,20220603,20220404,20220613,EXP,,FR-MYLANLABS-2022M1024088,MYLAN,"Yazdanpanah Y, Leibowitch J, Bellet J, Lefebvre B, Allavena C, Katlama C, et al.. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial.. Lancet HIV. 2022;9:e79-e90",,,A,,Y,,,20220613,,MD,FR,FR,EFAVIRENZ,Adverse event;Depression;Drug resistance;Gene mutation;Myocardial infarction;Pathogen resistance;Virologic failure,206698232,OT,,,,,,,,,206698232,1,HIV infection
20672283,206722831,1,I,20090619,20220322,20220405,20220405,EXP,,FR-AUROBINDO-AUR-APL-2018-062546,AUROBINDO,"Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A, et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design.. 2018",42,YR,,F,Y,,,20220405,,HP,FR,FR,EFAVIRENZ,Drug resistance;Viral mutation identified,206722831,OT,,,,,,,,,206722831,1,HIV infection
20677484,206774842,2,F,,20220330,20220406,20220411,EXP,,CA-ROCHE-3064757,ROCHE,,54,YR,,M,Y,,,20220411,,HP,CA,,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,206774842,DE,,,,,,,,,206774842,1,Product used for unknown indication
20677502,206775021,1,I,,20220328,20220406,20220406,EXP,,IN-CIPLA LTD.-2022IN02071,CIPLA,"Mani M, Kannagai R, Ramalingam V, Lionel J, Christina S, Sachithanandham J et.al.. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission. Indian Journal of Medical Microbiology. 2015;33(2):225 to 230",,,,,Y,,,20220406,,HP,IN,IN,EFAVIRENZ,Drug resistance;Exposure during pregnancy;Maternal exposure during delivery,206775021,OT,,,,,,,,,206775021,1,Prophylaxis against HIV infection
20677503,206775032,2,F,,20220328,20220406,20220407,EXP,,IN-CIPLA LTD.-2022IN02073,CIPLA,"Mani M, Kannangai R, Ramalingam VV, Lionel J, Christina SA, Sachithanandham J et.al. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission. Indian Journal of Medical Microbiology. 2015;33 (2):225 to 230",,,,,Y,,,20220407,,HP,IN,IN,EFAVIRENZ,Drug resistance;Exposure during pregnancy;Maternal exposure during delivery;No adverse event,206775032,OT,,,,,,,,,206775032,1,Prophylaxis against HIV infection
20678009,206780091,1,I,,20220404,20220406,20220406,EXP,,IN-GILEAD-2022-0576395,GILEAD,"Francis AK, Jacob M, Koshy JM, Finny P. Tenofovir Induced Fanconi Syndrome Complicated by Bilateral Neck of Femur Fractures. Indian J Endocr Metab.. 2021;25(6):569-571. doi:10.4103/ijem.ijem_363_21",56,YR,A,F,Y,,,20220406,,HP,IN,IN,EFAVIRENZ,Fanconi syndrome acquired;Multiple fractures;Osteoporosis,206780091,OT,,,,,,,,,206780091,1,HIV infection
20678962,206789621,1,I,,20220330,20220406,20220406,EXP,,CA-ROCHE-3064466,ROCHE,,54,YR,,M,Y,,,20220406,,HP,CA,,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,206789621,OT,,,,,,,,,206789621,1,Bipolar disorder
20680058,206800582,2,F,,20220527,20220406,20220531,EXP,,CA-ROCHE-3064485,ROCHE,,54,YR,,M,Y,,,20220531,,HP,CA,,EFAVIRENZ,Depression;Drug interaction;Loss of personal independence in daily activities,206800582,OT,,,,,,,,,206800582,1,Bipolar disorder
20683138,206831381,1,I,,20220404,20220407,20220407,EXP,,US-GILEAD-2022-0576344,GILEAD,,23,YR,A,M,Y,,,20220407,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Blood HIV RNA increased;Drug ineffective;Feeling abnormal;Illness;Motion sickness;Nausea;Staphylococcal infection,206831381,DS,,,,,,,,,206831381,1,HIV infection
20687035,206870352,2,F,20150101,20220325,20220407,20220520,EXP,,US-JNJFOC-20200934182,JOHNSON AND JOHNSON,,,,A,M,Y,68.027,KG,20220520,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Arthritis;Bone demineralisation;Decreased activity;Depression;Diarrhoea;Economic problem;Emotional distress;Fatigue;Headache;Left ventricular failure;Osteonecrosis;Osteoporosis;Pain,206870352,OT,,,206870352,3,20100802,20170729,2553,DAY,206870352,1,HIV infection
20688532,206885322,2,F,20110825,20220404,20220408,20220415,EXP,,FR-ROCHE-2232721,ROCHE,"Pouga L, Pouga L, Santoro MM, Charpentier C, Di Carlo D, Romeo I, Artese A et al.. New Resistance Mutations to Nucleoside Reverse Transcriptase Inhibitors at Codon 184 of HIV-1 Reverse Transcriptase (M184L and M184T).. Chemical biology + drug design. 2019;93(1):50-9.",35,YR,,F,Y,,,20220415,,HP,FR,FR,EFAVIRENZ,Drug resistance;Pathogen resistance;Treatment failure;Viral mutation identified,206885322,OT,,,,,,,,,206885322,1,HIV infection
20690928,206909281,1,I,,20220322,20220408,20220408,EXP,,IL-GLAXOSMITHKLINE-IL2022057522,GLAXOSMITHKLINE,,,,E,,Y,,,20220408,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Drug interaction;Gastrointestinal disorder;Hyperlipidaemia;Hypersensitivity;Nervous system disorder;Osteoporosis;Renal disorder,206909281,OT,,,,,,,,,206909281,1,HIV infection
20690931,206909311,1,I,,20220322,20220408,20220408,EXP,,IL-VIIV HEALTHCARE LIMITED-IL2022057522,VIIV,,,,E,,Y,,,20220408,,HP,IL,IL,EFAVIRENZ,Cardiovascular disorder;Drug interaction;Gastrointestinal disorder;Hyperlipidaemia;Hypersensitivity;Nervous system disorder;Osteoporosis;Renal disorder,206909311,OT,,,,,,,,,206909311,1,HIV infection
20694110,206941102,2,F,,20220520,20220411,20220527,EXP,,CA-ROCHE-3065639,ROCHE,,44,YR,,M,Y,,,20220527,,HP,CA,,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,206941102,HO,,,,,,,,,206941102,1,Depression
20699170,206991701,1,I,,20220401,20220412,20220412,EXP,,US-LUPIN PHARMACEUTICALS INC.-2022-05127,LUPIN,"Hammond KP, Nielsen C, Linnebur SA, Langness JA, Ray G, Maron P, et al. Priapism induced by boceprevir-CYP3A4 inhibition and ?-Adrenergic blockade: Case report. Clinical Infectious Diseases. 2014;58:35-38",44,YR,,M,Y,,,20220412,,HP,US,US,EFAVIRENZ + EMTRICITABINA + TENOFOVIR DISOPROXIL FUMARATO,Adrenergic syndrome;Drug interaction;Priapism,206991701,OT,,,,,,,,,206991701,1,Affective disorder
20702235,207022351,1,I,,20220405,20220412,20220412,EXP,,CA-009507513-2204CAN002342,MERCK,,54,YR,,M,Y,,,20220412,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207022351,OT,,,,,,,,,207022351,1,Product used for unknown indication
20703217,207032171,1,I,,20220403,20220413,20220413,EXP,,IN-HETERO-HET2022IN00830,HETERO,"Francis AK, Jacob M, Koshy JM, Finny P. Tenofovir Induced Fanconi Syndrome Complicated by Bilateral Neck of Femur Fractures. Indian Journal of Endocrinology and Metabolism. 2021;25(6):569-571",56,YR,,F,Y,,,20220413,,HP,IN,IN,EFAVIRENZ,Fanconi syndrome;Osteomalacia;Osteoporosis,207032171,OT,,,,,,,,,207032171,1,HIV infection
20703717,207037171,1,I,,20220403,20220413,20220413,EXP,,IN-HETERO-HET2022IN00829,HETERO,"Sarma GR, Delon Dsouza SS, Prakash P. Efavirenz-Induced Delayed Onset Cerebellar Ataxia and Encephalopathyx. Annals of Indian Academy of Neurology. 2022;25(1):153-155",23,YR,,F,Y,28,KG,20220413,,MD,IN,IN,EFAVIRENZ,Cerebellar ataxia;Encephalopathy;Toxicity to various agents,207037171,OT,,,207037171,1,2017,,,,207037171,1,HIV infection
20704669,207046691,1,I,20220407,20220411,20220413,20220413,PER,,US-ALKERMES INC.-ALK-2022-001765,ALKERMES,,53,YR,,F,Y,63.492,KG,20220413,,CN,US,US,SUSTIVA,Diarrhoea;Fatigue;Infectious mononucleosis;Nausea,,,,,207046691,1,20220406,,,,207046691,1,Alcoholism
20707501,207075011,1,I,,20220405,20220413,20220413,EXP,,CA-009507513-2204CAN002353,MERCK,,54,YR,,M,Y,,,20220413,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207075011,OT,,,,,,,,,207075011,1,HIV infection
20707845,207078451,1,I,,20220107,20220414,20220414,PER,,US-STRIDES ARCOLAB LIMITED-2021SP029351,STRIDES,"Brasher WP, Bvumbwe M, Kazembe PN.. Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment.. Malawi-Med-J. 2020;32(4):229-231",16,YR,,M,Y,,,20220414,,HP,US,US,EFAVIRENZ,Ataxia;Encephalopathy;Neurotoxicity;Toxicity to various agents,207078451,HO,,,207078451,1,2012,,3,DAY,207078451,1,HIV infection WHO clinical stage I
20713124,207131241,1,I,20220407,,20220414,20220414,DIR,FDA-CDER-CTU-2022-28781,,FDA-CTU,,68,YR,,M,N,,,20220414,N,PH,US,,EFAVIRENZ,Death,207131241,DE,207131241,HP,207131241,1,20211214,20220407,,,207131241,1,HIV infection
20716941,207169411,1,I,,20220404,20220416,20220416,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-020454,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220416,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207169411,OT,,,,,,,,,207169411,1,Product used for unknown indication
20724681,207246811,1,I,,20220411,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027446,TEVA,,54,YR,A,M,Y,,,20220419,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207246811,OT,,,,,,,,,207246811,1,HIV infection
20724688,207246881,1,I,,20220411,20220419,20220419,EXP,,CA-TEVA-2022-CA-2027451,TEVA,,54,YR,A,M,Y,,,20220419,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207246881,OT,,,,,,,,,207246881,1,HIV infection
20731145,207311451,1,I,,20220413,20220420,20220420,EXP,,CA-MYLANLABS-2022M1028568,MYLAN,,54,YR,,M,Y,,,20220420,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207311451,OT,,,,,,,,,207311451,1,Product used for unknown indication
20732187,207321871,1,I,,20220413,20220420,20220420,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2022GSK065960,VIIV,"Badat A, Lowton K. Case study: New onset of neuropsychiatric symptoms following switching to a dolutegravir regimen. South African Journal of Psychiatry. 2022;28(0)",32,YR,,M,Y,,,20220420,,HP,ZA,ZA,EFAVIRENZ,Aggression;Condition aggravated;Confusional state;Dizziness;Fall;Haemothorax;Humerus fracture;Insomnia;Neuropsychiatric symptoms;Pericardial effusion;Restlessness;Rib fracture;Sleep disorder;Soliloquy;Thinking abnormal,207321871,OT,,,,,,,,,207321871,1,HIV infection
20737909,207379091,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02589,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207379091,OT,,,,,,,,,207379091,1,HIV infection WHO clinical stage I
20737937,207379371,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA (EU) LIMITED-2022TZ02591,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207379371,OT,,,207379371,1,20100221,,,,207379371,1,HIV infection WHO clinical stage III
20738039,207380391,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02599,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380391,OT,,,207380391,1,20060626,,,,207380391,1,HIV infection WHO clinical stage III
20738089,207380891,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02605,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380891,OT,,,207380891,1,20070421,,,,207380891,1,HIV infection WHO clinical stage IV
20738093,207380931,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02537,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380931,OT,,,207380931,1,20120924,,,,207380931,1,HIV infection WHO clinical stage III
20738097,207380971,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02590,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207380971,OT,,,207380971,1,20100423,,,,207380971,1,HIV infection WHO clinical stage III
20738155,207381551,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02607,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.,. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207381551,OT,,,207381551,2,20121106,,,,207381551,1,HIV infection WHO clinical stage IV
20738177,207381771,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02611,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207381771,OT,,,207381771,1,20060527,,,,207381771,1,HIV infection WHO clinical stage IV
20738205,207382051,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02615,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207382051,OT,,,207382051,1,20140131,,,,207382051,1,HIV infection WHO clinical stage I
20738237,207382371,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02621,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207382371,OT,,,207382371,1,20130520,,,,207382371,1,HIV infection WHO clinical stage I
20738390,207383901,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02625,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SS, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207383901,OT,,,207383901,1,20151019,,,,207383901,1,HIV infection WHO clinical stage III
20738438,207384381,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02598,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207384381,OT,,,207384381,1,20050411,,,,207384381,1,HIV infection WHO clinical stage IV
20738439,207384391,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02596,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial chemotherapy. 2022;77:483-491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207384391,OT,,,207384391,1,20070730,,,,207384391,1,HIV infection WHO clinical stage IV
20738440,207384401,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02629,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207384401,OT,,,207384401,1,20050725,,,,207384401,1,HIV infection WHO clinical stage II
20738589,207385892,2,F,20131029,20220501,20220422,20220504,EXP,,ZA-GILEAD-2022-0578517,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",39,YR,A,M,Y,,,20220504,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207385892,OT,,,207385892,1,20131003,20131029,26,DAY,207385892,1,HIV infection
20738611,207386111,1,I,,20220418,20220422,20220422,EXP,,ZA-GILEAD-2022-0578712,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",37,YR,A,M,Y,,,20220422,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207386111,OT,,,,,,,,,207386111,1,HIV infection
20738710,207387101,1,I,,20220418,20220422,20220422,EXP,,ZA-GILEAD-2022-0578713,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",33,YR,A,M,Y,,,20220422,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207387101,OT,,,,,,,,,207387101,1,HIV infection
20738760,207387601,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02614,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.,. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207387601,OT,,,207387601,1,20060629,,,,207387601,1,HIV infection WHO clinical stage III
20738762,207387621,1,I,,20220411,20220422,20220422,EXP,,TZ-CIPLA LTD.-2022TZ02616,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220422,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207387621,OT,,,,,,,,,207387621,1,HIV infection WHO clinical stage III
20738779,207387791,1,I,,20220418,20220422,20220422,EXP,,ZA-GILEAD-2022-0578714,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36,YR,A,M,Y,,,20220422,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207387791,OT,,,,,,,,,207387791,1,HIV infection
20738861,207388611,1,I,,20220418,20220422,20220422,EXP,,ZA-GILEAD-2022-0578715,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",44,YR,A,F,Y,,,20220422,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207388611,OT,,,,,,,,,207388611,1,HIV infection
20738947,207389471,1,I,,20220418,20220422,20220422,EXP,,ZA-GILEAD-2022-0578716,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36,YR,A,F,Y,,,20220422,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207389471,OT,,,,,,,,,207389471,1,HIV infection
20739137,207391372,2,F,,20220418,20220422,20220504,EXP,,ZA-GILEAD-2022-0578717,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36,YR,A,M,Y,,,20220504,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207391372,DE,,,,,,,,,207391372,1,HIV infection
20739332,207393322,2,F,,20220418,20220422,20220428,EXP,,ZA-GILEAD-2022-0578718,GILEAD,"Do Vale C L, Naicker S, Lippincott C K. Acute Interstitial Nephritis in Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Kidney International Reports. 2022;7:920-923. doi:10.1016/j.ekir.2021.12.008",36,YR,A,F,Y,,,20220428,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Immune reconstitution inflammatory syndrome associated tuberculosis,207393322,OT,,,,,,,,,207393322,1,HIV infection
20742958,207429581,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02620,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207429581,OT,,,207429581,1,20080327,,,,207429581,1,HIV infection WHO clinical stage III
20742959,207429591,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02626,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207429591,OT,,,207429591,1,20091013,,,,207429591,1,HIV infection CDC Group III
20742960,207429601,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02618,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207429601,OT,,,207429601,1,20160129,,,,207429601,1,HIV infection WHO clinical stage II
20743051,207430511,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02634,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430511,OT,,,207430511,1,20150121,,,,207430511,1,HIV infection
20743052,207430521,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02636,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430521,OT,,,207430521,1,20120517,,,,207430521,1,HIV infection WHO clinical stage II
20743053,207430531,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02628,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430531,OT,,,207430531,1,20090917,,,,207430531,1,HIV infection WHO clinical stage III
20743055,207430551,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02630,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207430551,OT,,,207430551,1,20140709,,,,207430551,1,HIV infection CDC Group III
20743116,207431161,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02617,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431161,OT,,,207431161,1,20101021,,,,207431161,1,HIV infection WHO clinical stage II
20743129,207431291,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02631,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431291,OT,,,,,,,,,207431291,1,HIV infection WHO clinical stage III
20743149,207431491,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02633,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431491,OT,,,207431491,1,20120309,,,,207431491,1,HIV infection WHO clinical stage III
20743160,207431601,1,I,,20220411,20220425,20220425,EXP,,TZ-CIPLA LTD.-2022TZ02745,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et al.. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220425,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207431601,OT,,,207431601,1,20130515,,,,207431601,1,HIV infection WHO clinical stage II
20743473,207434731,1,I,,20220420,20220425,20220425,EXP,,CA-BAUSCH-BL-2022-009740,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220425,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207434731,OT,,,,,,,,,207434731,1,Bipolar disorder
20747843,207478431,1,I,,20220420,20220425,20220425,EXP,,CA-BAUSCH-BL-2022-009742,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220426,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207478431,OT,,,,,,,,,207478431,1,Bipolar disorder
20748123,207481231,1,I,,20220411,20220426,20220426,EXP,,TZ-CIPLA LTD.-2022TZ02639,CIPLA,"Henerico S, Kasang C, Mikasi SG, Kalluvya SE, Brauner JM, Abdul S et.al. Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in NorthWestern Tanzania. Journal of Antimicrobial Chemotherapy. 2022;77:483 to 491",,,,,Y,,,20220426,,HP,TZ,TZ,EFAVIRENZ,Virologic failure,207481231,OT,,,207481231,1,20090430,,,,207481231,1,HIV infection WHO clinical stage II
20750295,207502952,2,F,,20220502,20220426,20220516,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2022-015170,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220517,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,207502952,HO,,,,,,,,,207502952,1,Product used for unknown indication
20757165,207571652,2,F,,20220420,20220427,20220624,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK069737,VIIV,,,,,,Y,,,20220624,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,207571652,OT,,,,,,,,,207571652,1,Bipolar disorder
20757166,207571662,2,F,,20220420,20220427,20220624,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK069612,VIIV,,,,,,Y,,,20220624,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,207571662,OT,,,,,,,,,207571662,1,Bipolar disorder
20762313,207623131,1,I,20220402,20220426,20220428,20220428,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC069574,VIIV,,22,YR,,M,Y,,,20220428,,HP,CN,CN,EFAVIRENZ,Abdominal discomfort;Abdominal distension;Granulocyte count decreased;Nausea,207623131,HO,,,207623131,1,20220328,20220407,10,DAY,207623131,1,Acquired immunodeficiency syndrome
20762345,207623451,1,I,20220402,20220426,20220428,20220428,EXP,,CN-GLAXOSMITHKLINE-CN2022APC069574,GLAXOSMITHKLINE,,22,YR,,M,Y,,,20220428,,HP,CN,CN,EFAVIRENZ,Abdominal discomfort;Abdominal distension;Granulocyte count decreased;Nausea,207623451,HO,,,207623451,1,20220328,20220407,10,DAY,207623451,1,Acquired immunodeficiency syndrome
20780730,207807301,1,I,,20220420,20220504,20220504,EXP,,KE-CIPLA LTD.-2022KE02836,CIPLA,"Khamadi S, Wexler C, Lwembe R, Maosa N, Maloba M, Sandbulte M et al.. HIV Drug Resistance in Kenyan Infants Diagnosed with HIV and Their Mothers. The Pediatric Infectious Disease Journal. 2022;41 (4):312 to 314",,,,,Y,,,20220504,,HP,KE,KE,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,207807301,OT,,,,,,,,,,,
20780733,207807331,1,I,,20220420,20220504,20220504,EXP,,KE-CIPLA LTD.-2022KE02838,CIPLA,"Khamadi S, Wexler C, Lwembe R, Maosa N, Maloba M, Sandbulte M et.al. HIV Drug Resistance in Kenyan Infants Diagnosed with HIV and Their Mothers. The Pediatric Infectious Disease Journal. 2022;41 (4):312 to 314",,,,,Y,,,20220504,,HP,KE,KE,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Human immunodeficiency virus transmission,207807331,OT,,,,,,,,,,,
20780734,207807341,1,I,,20220420,20220504,20220504,EXP,,KE-CIPLA LTD.-2022KE02833,CIPLA,"Khamadi S, Wexler C, Lwembe R, Maosa N, Maloba M, Sandbulte M et.al. HIV Drug Resistance in Kenyan Infants Diagnosed with HIV and Their Mothers. The Pediatric Infectious Disease Journal. 2022;41:4:312 to 314",,,,,Y,,,20220504,,HP,KE,KE,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,207807341,OT,,,,,,,,,207807341,1,HIV infection CDC category B
20781260,207812601,1,I,,20220429,20220504,20220504,EXP,,CA-ROCHE-3088022,ROCHE,,54,YR,,M,Y,,,20220504,,HP,CA,,SUSTIVA,Depression;Drug interaction,207812601,OT,,,,,,,,,207812601,1,Bipolar disorder
20810420,208104201,1,I,,20220504,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK075381,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104201,OT,,,208104201,6,,,23,MON,208104201,1,HIV infection CDC category C
20810421,208104211,1,I,,20220504,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK075381,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104211,OT,,,208104211,6,,,23,MON,208104211,1,HIV infection CDC category C
20810470,208104701,1,I,,20220504,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK075399,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104701,OT,,,208104701,1,,,6,MON,208104701,1,HIV infection CDC category C
20810472,208104721,1,I,,20220504,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK075399,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104721,OT,,,208104721,1,,,6,MON,208104721,1,HIV infection CDC category C
20810474,208104741,1,I,,20220504,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK074567,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104741,OT,,,,,,,,,208104741,1,HIV infection CDC category C
20810477,208104771,1,I,,20220504,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK074567,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208104771,OT,,,,,,,,,208104771,1,HIV infection CDC category C
20810744,208107441,1,I,,20220504,20220510,20220510,EXP,,MW-VIIV HEALTHCARE LIMITED-MW2022GSK075600,VIIV,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Drug interaction;Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208107441,OT,,,,,,,,,208107441,1,HIV infection CDC category C
20810745,208107451,1,I,,20220504,20220510,20220510,EXP,,MW-GLAXOSMITHKLINE-MW2022GSK075600,GLAXOSMITHKLINE,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;9(5)",,,A,M,Y,,,20220510,,HP,MW,MW,EFAVIRENZ,Drug interaction;Multiple-drug resistance;Pathogen resistance;Viral mutation identified,208107451,OT,,,,,,,,,208107451,1,HIV infection CDC category C
20812534,208125342,2,F,20171006,20220506,20220511,20220518,EXP,GB-AUROBINDO-AUR-APL-2018-033634,GB-BAUSCH-BL-2022-011356,BAUSCH AND LOMB,,,,,M,Y,,,20220518,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,208125342,CA,,,208125342,4,20171006,20180205,4,MON,208125342,1,Foetal exposure during pregnancy
20825633,208256331,1,I,,20220506,20220513,20220513,EXP,,IN-ROCHE-3096059,ROCHE,"Phatak U, Badakh D Squamous cell carcinoma of the rectum in an HIV-1 patient on antiretroviral therapy. DOI: 10.4103/jcrt.JCRT-262-19. Journal of Cancer Research and Therapeutics 2021 Dec;17 (6):1556-8.",56,YR,,M,Y,,,20220513,,HP,IN,,EFAVIRENZ,Disease progression;Metastases to liver;Metastatic squamous cell carcinoma,208256331,HO,,,,,,,,,208256331,1,Squamous cell carcinoma
20834776,208347761,1,I,20180101,20220506,20220516,20220516,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2022APC074744,VIIV,"Li Q, Zhang W, Sun Y, Huang W, Deng C, Yuan J. Aplastic anemia induced by compound sulfamethoxazole in a patient with HIV infection: a case report. Chinese Journal of Infection and Chemotherapy. 2022;22(2):207-209",,,,,Y,,,20220516,,MD,CN,CN,EFAVIRENZ,Aplastic anaemia;Asthenia;Bone marrow failure;Condition aggravated;Marasmus;Marrow hyperplasia;Multiple-drug resistance;Myelosuppression;Pallor;Papule;Pathogen resistance;Pneumonia fungal;Tachypnoea;Thrombocytopenia;Virologic failure;Weight decreased,208347761,OT,,,208347761,1,20180520,20190118,243,DAY,208347761,1,Opportunistic infection prophylaxis
20834777,208347771,1,I,20180101,20220506,20220516,20220516,EXP,,CN-GLAXOSMITHKLINE-CN2022APC074744,GLAXOSMITHKLINE,"Li Q, Zhang W, Sun Y, Huang W, Deng C, Yuan J. Aplastic anemia induced by compound sulfamethoxazole in a patient with HIV infection: a case report. Chinese Journal of Infection and Chemotherapy. 2022;22(2):207-209",,,,,Y,,,20220516,,MD,CN,CN,EFAVIRENZ,Aplastic anaemia;Asthenia;Bone marrow failure;Condition aggravated;Marasmus;Marrow hyperplasia;Multiple-drug resistance;Myelosuppression;Pallor;Papule;Pathogen resistance;Pneumonia fungal;Tachypnoea;Thrombocytopenia;Virologic failure;Weight decreased,208347771,OT,,,208347771,1,20180520,20190118,243,DAY,208347771,1,Opportunistic infection prophylaxis
20836821,208368211,1,I,,20220502,20220517,20220517,EXP,,ZM-ALKEM LABORATORIES LIMITED-ZM-ALKEM-2022-04414,ALKEM,"Kabengele C, M^hango H, Mweemba D, Malumani M. A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. Pan Afr Med J. 2021;39:73",40,YR,,F,Y,,,20220517,,MD,ZM,ZM,EFAVIRENZ,Dementia;Dermatitis;Nicotinic acid deficiency;Skin fissures;Skin hyperpigmentation,208368211,OT,,,,,,,,,208368211,1,Tuberculosis
20842957,208429571,1,I,,20220504,20220518,20220518,EXP,,IN-CIPLA LTD.-2022IN03053,CIPLA,"Mangal V, Murari T, Gaikwad SN, Kaur K.. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy - A case report. Indian Journal of Nephrology. 2022;32:2:175 to 178",,,,,Y,,,20220518,,HP,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome;Femur fracture;Hydronephrosis;Nephrolithiasis;Osteomalacia;Pyelitis,208429571,HO,,,,,,,,,208429571,1,HIV infection
20843965,208439651,1,I,,20120617,20220518,20220518,EXP,,US-GLENMARK PHARMACEUTICALS-GGEL20120600811,GLENMARK,"St Clair K,Maguire J. Role of fluconazole in a case of rapid onset ritonavir and inhaled fluticasone-associated secondary adrenal insufficiency.. International Journal of STD and AIDS 2012 May;23 (5):371-372.",52,YR,,M,Y,,,20220518,,HP,US,US,EFAVIRENZ,Cushing's syndrome;Drug interaction;Secondary adrenocortical insufficiency,208439651,OT,,,208439651,1,,,7,DAY,208439651,1,Oral candidiasis
20849982,208499821,1,I,,20220517,20220519,20220519,EXP,,GB-GILEAD-2022-0582191,GILEAD,,,,A,M,Y,,,20220519,,CN,GB,GB,EFAVIRENZ,Malaise,208499821,HO,,,,,,,,,208499821,1,HIV infection
20855923,208559232,2,F,,20220616,20220520,20220621,EXP,,ES-VIIV HEALTHCARE LIMITED-ES2022GSK078393,VIIV,,,,,,Y,,,20220621,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,208559232,OT,,,208559232,2,200501,200501,,,208559232,1,HIV infection
20855924,208559242,2,F,,20220616,20220520,20220621,EXP,,ES-GLAXOSMITHKLINE-ES2022GSK078393,GLAXOSMITHKLINE,,,,,,Y,,,20220621,,HP,ES,ES,EFAVIRENZ,Acquired immunodeficiency syndrome;Multiple-drug resistance;Pathogen resistance;Progressive multifocal leukoencephalopathy;Therapy non-responder;Viral mutation identified;Virologic failure,208559242,OT,,,208559242,2,200501,200501,,,208559242,1,HIV infection
20858432,208584321,1,I,,20220517,20220521,20220521,EXP,,CA-009507513-2205CAN005476,MERCK,,54,YR,,M,Y,,,20220521,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208584321,HO,,,,,,,,,208584321,1,HIV infection
20859579,208595792,2,F,,20220527,20220523,20220530,EXP,,CA-GILEAD-2022-0582268,GILEAD,,54,YR,A,M,Y,,,20220530,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208595792,HO,,,,,,,,,208595792,1,Product used for unknown indication
20859607,208596071,1,I,20070101,20220516,20220523,20220523,EXP,,CA-BAUSCH-BL-2022-012432,BAUSCH AND LOMB,"Harris M, Larsen G, Montaner J. Exacerbation of depression associated with starting raltegravir: A report of four cases. AIDS. 2008;22(14):.",54,YR,,M,Y,,,20220523,,MD,CA,CA,EFAVIRENZ,Drug interaction;Psychiatric decompensation,208596071,OT,,,208596071,2,2007,,2,DAY,208596071,1,Depression
20859716,208597161,1,I,,20220510,20220523,20220523,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039322,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220523,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,208597161,HO,,,,,,,,,208597161,1,Product used for unknown indication
20861199,208611991,1,I,,20220510,20220523,20220523,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039077,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220523,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Hospitalisation;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208611991,OT,,,,,,,,,208611991,1,HIV infection
20861942,208619421,1,I,,20220516,20220523,20220523,EXP,,AT-GILEAD-2022-0582095,GILEAD,,85,YR,E,F,Y,,,20220523,,MD,AT,AT,EFAVIRENZ,Drug interaction;Nephropathy toxic,208619421,OT,,,208619421,1,200205,200208,,,208619421,1,Product used for unknown indication
20862193,208621931,1,I,,20220510,20220523,20220523,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-045861,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220523,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Death,208621931,DE,,,,,,,,,208621931,1,HIV infection
20862425,208624251,1,I,,20220510,20220523,20220523,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039291,BRISTOL MYERS SQUIBB,,54,YR,A,M,Y,,,20220523,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Adverse event;Depression;Drug interaction;Loss of personal independence in daily activities,208624251,HO,,,,,,,,,208624251,1,HIV infection
20862603,208626031,1,I,,20220513,20220523,20220523,EXP,,CA-ABBVIE-22K-028-4401503-00,ABBVIE,,54,YR,,M,Y,,,20220523,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration,208626031,OT,,,,,,,,,208626031,1,Product used for unknown indication
20865479,208654791,1,I,,20220517,20220524,20220524,EXP,,CA-GILEAD-2022-0582425,GILEAD,,52,YR,A,M,Y,,,20220524,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208654791,OT,,,,,,,,,208654791,1,HIV infection
20866452,208664522,2,F,,20220530,20220524,20220601,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME080792,VIIV,,,,,,Y,,,20220601,,MD,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,208664522,OT,,,208664522,1,1998,,,,208664522,1,HIV infection
20868399,208683991,1,I,20160101,20220523,20220524,20220524,EXP,,US-GILEAD-2022-0582842,GILEAD,,37,YR,A,M,Y,,,20220524,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Bladder cancer;Hodgkin's disease stage III,208683991,OT,,,208683991,1,201407,2018,,,208683991,1,HIV infection
20868859,208688592,2,F,,20220516,20220524,20220613,EXP,,DK-GILEAD-2022-0582165,GILEAD,"Gulden T, Yahyavi S, Lodding I, Jensen J, Blomberg JM. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report. Bone Reports. 2021;15;101119:NI. doi:10.1016/j.bonr.2021.101119",67,YR,E,M,Y,,,20220613,,HP,DK,DK,EFAVIRENZ,Dehydration;Diarrhoea;Off label use;Vomiting,208688592,HO,,,,,,,,,208688592,1,HIV infection
20870910,208709101,1,I,,20220510,20220525,20220525,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-2022-039152,BRISTOL MYERS SQUIBB,,52,YR,A,M,Y,,,20220525,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia,208709101,OT,,,,,,,,,208709101,1,HIV infection
20871449,208714493,3,F,,20220610,20220525,20220623,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2022-042104,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220624,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Hospitalisation;Life expectancy shortened;Lung cancer metastatic;Lung neoplasm malignant;Malaise;Metastases to central nervous system,208714493,HO,,,,,,,,,208714493,1,Product used for unknown indication
20871852,208718522,2,F,,20220527,20220525,20220603,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022082351,VIIV,,,,,,Y,,,20220603,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208718522,HO,,,,,,,,,208718522,1,Product used for unknown indication
20871865,208718652,2,F,,20220527,20220525,20220603,EXP,,CA-GLAXOSMITHKLINE-CA2022082351,GLAXOSMITHKLINE,,,,,,Y,,,20220603,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208718652,HO,,,,,,,,,208718652,1,Product used for unknown indication
20872212,208722121,1,I,,20220520,20220525,20220525,EXP,,CA-ROCHE-3101481,ROCHE,,54,YR,,M,Y,,,20220525,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,208722121,OT,,,,,,,,,208722121,1,HIV infection
20876834,208768341,1,I,,20220519,20220526,20220526,EXP,,ES-MYLANLABS-2022M1039325,MYLAN,"Rial-Crestelo D, Bisbal O, Font R, De Lagarde M, Pinto A, Arce-Garcia O, et al. Incidence and Severity of SARS-CoV-2 Infection in HIV-Infected Individuals During the First Year of the Pandemic. J-Acquir-Immune-Defic-Syndr 2022;89(5):511-518.",66,YR,,,Y,,,20220526,,MD,ES,ES,EFAVIRENZ,Drug ineffective for unapproved indication;Off label use,208768341,HO,,,,,,,,,208768341,1,COVID-19
20877650,208776501,1,I,,20220518,20220526,20220526,EXP,,CA-APOTEX-2022AP008239,APOTEX,,54,YR,,M,Y,,,20220526,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208776501,HO,,,,,,,,,208776501,1,HIV infection
20879536,208795361,1,I,,20220517,20220526,20220526,EXP,,CA-009507513-2205CAN005187,MERCK,,52,YR,,M,Y,,,20220526,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208795361,OT,,,,,,,,,208795361,1,HIV infection
20882376,208823762,2,F,,20220603,20220527,20220607,EXP,,CA-009507513-2205CAN005209,MERCK,,54,YR,,M,Y,,,20220607,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,208823762,OT,,,,,,,,,208823762,1,Product used for unknown indication
20883075,208830751,1,I,,20220525,20220527,20220527,EXP,,CA-BAUSCH-BL-2022-012990,BAUSCH AND LOMB,,,,,M,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,208830751,HO,,,,,,,,,208830751,1,Product used for unknown indication
20883079,208830791,1,I,,20220525,20220527,20220527,EXP,,CA-BAUSCH-BL-2022-012991,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220527,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208830791,HO,,,,,,,,,208830791,1,Depression
20883081,208830811,1,I,,20220525,20220527,20220527,EXP,,CA-BAUSCH-BL-2022-012994,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,208830811,DE,,,,,,,,,208830811,1,Bipolar disorder
20884066,208840661,1,I,,20220525,20220527,20220527,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084848,VIIV,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,208840661,OT,,,,,,,,,208840661,1,HIV infection
20884074,208840741,1,I,,20220525,20220527,20220527,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084848,GLAXOSMITHKLINE,,,,,,Y,,,20220527,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,208840741,DE,,,,,,,,,208840741,1,HIV infection
20884822,208848222,2,F,20220424,20220608,20220527,20220615,EXP,ES-AEMPS-1191015,ES-PFIZER INC-202200757835,PFIZER,,55,YR,,F,Y,,,20220615,,MD,ES,ES,EFAVIRENZ/EMTRICITABINA/TENOFOVIR DISOPROXILO TEVA,Drug withdrawal syndrome;Overdose;Seizure;Syncope,208848222,HO,,,208848222,1,20220424,20220430,7,DAY,208848222,5,HIV infection
20891017,208910172,2,F,20200101,20220601,20220530,20220606,EXP,,PT-VIIV HEALTHCARE LIMITED-PT2022EME082997,VIIV,,,,,,Y,,,20220606,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,208910172,OT,,,208910172,1,2013,2014,,,208910172,1,HIV infection
20891018,208910182,2,F,20200101,20220601,20220530,20220606,EXP,,PT-GLAXOSMITHKLINE-PT2022EME082997,GLAXOSMITHKLINE,,,,,,Y,,,20220606,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,208910182,OT,,,208910182,1,2013,2014,,,208910182,1,HIV infection
20891389,208913891,1,I,,20220524,20220530,20220530,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-2022-047212,BRISTOL MYERS SQUIBB,,85,YR,E,F,Y,,,20220530,,MD,AT,AT,EFAVIRENZ,Drug interaction;Nephropathy toxic,208913891,OT,,,208913891,2,200205,200208,3,MON,208913891,1,Cardiovascular disorder
20891666,208916661,1,I,,20220517,20220530,20220530,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022083222,VIIV,,,,,,Y,,,20220530,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208916661,OT,,,,,,,,,208916661,1,HIV infection
20891667,208916671,1,I,,20220517,20220530,20220530,EXP,,CA-GLAXOSMITHKLINE-CA2022083222,GLAXOSMITHKLINE,,,,,,Y,,,20220530,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,208916671,OT,,,,,,,,,208916671,1,HIV infection
20892144,208921441,1,I,,20220525,20220530,20220530,EXP,,CA-BAUSCH-BL-2022-012993,BAUSCH AND LOMB,,54,YR,,M,Y,,,20220530,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,208921441,OT,,,,,,,,,208921441,1,Product used for unknown indication
20892665,208926651,1,I,,20220526,20220531,20220531,EXP,,CA-ABBVIE-22K-028-4414704-00,ABBVIE,,54,YR,,M,Y,,,20220531,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208926651,HO,,,,,,,,,208926651,1,HIV infection
20893463,208934631,1,I,20090207,20220407,20220531,20220531,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-2022-045158,BRISTOL MYERS SQUIBB,,36,YR,A,M,Y,,,20220531,,HP,JP,JP,EFAVIRENZ,COVID-19;Drug eruption;Herpes zoster;Insomnia;Spirochaetal infection,208934631,OT,,,208934631,1,20090208,20120821,1291,DAY,208934631,1,HIV infection
20898441,208984411,1,I,,20220517,20220601,20220601,EXP,,CA-AUROBINDO-AUR-APL-2022-018761,AUROBINDO,,54,YR,,M,Y,,,20220601,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,208984411,HO,,,,,,,,,208984411,1,Psychotic disorder
20899782,208997821,1,I,20201129,20220525,20220601,20220601,EXP,,CN-GILEAD-2022-0583244,GILEAD,"Qing Z, Fang Z. A case of HIV infection complicated with toxic epidermal necrolysis. Chin J Diffic and Compl Cas. 2022;21:UNK. doi:10.3969 / j. issn.1671-6450.2022.05.019",20,YR,A,M,Y,,,20220601,,MD,CN,CN,EFAVIRENZ,Toxic epidermal necrolysis,208997821,HO,,,208997821,1,20201023,,,,208997821,1,HIV infection
20900443,209004431,1,I,,20220519,20220601,20220601,PER,,ES-LUPIN PHARMACEUTICALS INC.-2022-07828,LUPIN,"Rial-Crestelo D, Bisbal O, Font R, De Lagarde M, Pinto A, Arce-Garcia O, et al. Incidence and severity of SARS-CoV-2 infection in HIV-infected individuals during the first year of the pandemic. Journal of Acquired Immune Deficiency Syndromes. 2022;89(5):511-518",66,YR,,,Y,,,20220601,,MD,ES,ES,EFAVIRENZ,Drug ineffective for unapproved indication;Off label use,209004431,HO,,,,,,,,,209004431,1,COVID-19
20900821,209008212,2,F,,20220601,20220601,20220606,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084846,VIIV,,,,,,Y,,,20220606,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,209008212,HO,,,,,,,,,209008212,1,Product used for unknown indication
20900822,209008221,1,I,,20220525,20220601,20220601,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK086027,VIIV,,,,,,Y,,,20220601,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,209008221,OT,,,,,,,,,209008221,1,Product used for unknown indication
20900824,209008241,1,I,,20220525,20220601,20220601,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK084853,VIIV,,,,,,Y,,,20220601,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209008241,OT,,,,,,,,,209008241,1,HIV infection
20900825,209008252,2,F,,20220601,20220601,20220606,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084846,GLAXOSMITHKLINE,,,,,,Y,,,20220606,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,209008252,HO,,,,,,,,,209008252,1,Product used for unknown indication
20900832,209008321,1,I,,20220525,20220601,20220601,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK086027,GLAXOSMITHKLINE,,,,,,Y,,,20220601,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,209008321,OT,,,,,,,,,209008321,1,Product used for unknown indication
20900836,209008361,1,I,,20220525,20220601,20220601,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK084853,GLAXOSMITHKLINE,,,,,,Y,,,20220601,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209008361,HO,,,,,,,,,209008361,1,HIV infection
20901234,209012341,1,I,,20220520,20220601,20220601,EXP,,CA-ROCHE-3101619,ROCHE,,54,YR,,M,Y,,,20220601,,HP,CA,,SUSTIVA,Depression;Drug interaction,209012341,OT,,,,,,,,,209012341,1,Bipolar disorder
20902432,209024321,1,I,,20220527,20220601,20220601,EXP,,UG-MYLANLABS-2022M1041517,MYLAN,,37,YR,,F,Y,,,20220601,,HP,UG,UG,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209024321,OT,,,209024321,1,20210106,20210105,958,DAY,209024321,1,HIV infection
20907220,209072201,1,I,,20220526,20220602,20220602,EXP,,CA-ALLERGAN-2217864US,ALLERGAN,,,,,M,Y,,,20220602,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209072201,HO,,,,,,,,,209072201,1,Psychotic disorder
20907257,209072571,1,I,,20220602,20220602,20220602,EXP,,PT-ABBVIE-22K-130-4419333-00,ABBVIE,,56,YR,,M,Y,,,20220602,,CN,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,209072571,OT,,,209072571,1,1998,,,,209072571,1,HIV infection
20909505,209095051,1,I,,20220531,20220603,20220603,EXP,,CA-ROCHE-3109005,ROCHE,,,,,M,Y,,,20220603,,HP,CA,,SUSTIVA,Depression;Drug interaction,209095051,HO,,,,,,,,,209095051,1,Product used for unknown indication
20910771,209107711,1,I,,20220524,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041639,TEVA,,54,YR,A,M,Y,,,20220603,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209107711,HO,,,,,,,,,209107711,1,HIV infection
20910772,209107721,1,I,,20220524,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041638,TEVA,,,,,M,Y,,,20220603,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,209107721,HO,,,,,,,,,209107721,1,Product used for unknown indication
20910829,209108291,1,I,,20220524,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041644,TEVA,,54,YR,A,M,Y,,,20220603,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,209108291,OT,,,,,,,,,209108291,1,HIV infection
20910851,209108511,1,I,,20220524,20220603,20220603,EXP,,CA-TEVA-2022-CA-2041645,TEVA,,54,YR,A,M,Y,,,20220603,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,209108511,DE,,,,,,,,,209108511,1,Product used for unknown indication
20916488,209164882,2,F,20100629,20220623,20220605,20220630,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-173285",BOEHRINGER INGELHEIM,,43,YR,A,F,Y,,,20220630,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Alanine aminotransferase increased;Aspartate aminotransferase increased;Caesarean section;Hepatic cytolysis;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,209164882,CA,,,209164882,1,20090101,20100610,525,DAY,209164882,1,Antiretroviral therapy
20916899,209168991,1,I,,20220529,20220605,20220605,EXP,,IN-Laurus-001256,LAURUS LABS LIMITED,IN-Laurus-001256-01_Initial Source Document,54,YR,A,F,Y,,,20220603,,HP,IN,,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Calculus urinary;Condition aggravated;Fanconi syndrome;Femoral neck fracture;Metabolic acidosis;Nephrolithiasis;Osteomalacia;Pulmonary embolism;Sepsis;Urinary tract infection,209168991,HO,,,,,,,,,209168991,1,HIV infection
20918819,209188191,1,I,,20220531,20220606,20220606,EXP,,CA-ROCHE-3108784,ROCHE,,54,YR,,M,Y,,,20220606,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,209188191,DE,,,,,,,,,209188191,1,HIV infection
20921192,209211921,1,I,,20220525,20220606,20220606,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-048190,BRISTOL MYERS SQUIBB,,56,YR,A,M,Y,,,20220606,,MD,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,209211921,OT,,,209211921,1,2002,,,,209211921,1,HIV infection
20921652,209216521,1,I,,20220531,20220606,20220606,EXP,,CA-ROCHE-3108782,ROCHE,,54,YR,,M,Y,,,20220607,,HP,CA,,EFAVIRENZ;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,209216521,HO,,,,,,,,,209216521,1,Product used for unknown indication
20923706,209237061,1,I,20200101,20220601,20220607,20220607,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-051945,BRISTOL MYERS SQUIBB,,73,YR,E,F,Y,,,20220607,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209237061,OT,,,209237061,1,2013,2014,1,YR,209237061,1,HIV infection
20923847,209238471,1,I,,20220531,20220607,20220607,EXP,,CA-ROCHE-3109019,ROCHE,,54,YR,,M,Y,,,20220607,,HP,CA,,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209238471,HO,,,,,,,,,209238471,1,Depression
20927610,209276101,1,I,20200101,20220607,20220607,20220607,EXP,,PT-ABBVIE-22K-130-4424610-00,ABBVIE,,73,YR,,F,Y,,,20220607,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209276101,OT,,,209276101,1,2014,2018,,,209276101,1,HIV infection
20929239,209292391,1,I,,20220526,20220608,20220608,EXP,,PT-AUROBINDO-AUR-APL-2022-020016,AUROBINDO,,56,YR,,M,Y,,,20220608,,MD,PT,PT,EFAVIRENZ,Blood creatinine increased;Chronic kidney disease;Dyslipidaemia;Glomerular filtration rate decreased;Hypertension;Insomnia;Nephrolithiasis;Osteoporosis;Renal colic;Weight increased,209292391,OT,,,209292391,1,2002,,,,209292391,1,HIV infection
20929273,209292732,2,F,,20220607,20220608,20220620,EXP,,ZA-LAURUS LABS LIMITED-2022LAU000004,LAURUS LABS LIMITED,,28,YR,,F,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,209292732,OT,,,209292732,1,20180711,,,,209292732,1,Asymptomatic HIV infection
20929340,209293401,1,I,20171006,20220525,20220608,20220608,EXP,,GB-AUROBINDO-AUR-APL-2022-020239,AUROBINDO,,43,YR,,F,Y,,,20220608,,HP,GB,GB,EFAVIRENZ,Abortion spontaneous;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,209293401,OT,,,209293401,1,20171006,20180205,4,MON,209293401,1,HIV infection
20929353,209293531,1,I,,20220529,20220608,20220608,EXP,,IN-HETERO-HET2022IN01229,HETERO,"Mangal V, Murari T, Gaikwad SN, Kaur K. Simultaneous occurrence of nephrolithiasis, fanconi syndrome, and nephro-osteopathy in a patient on first-line antiretroviral therapy-A case report. Indian Journal of Nephrology. 2022;32(2):175-178",54,YR,,F,Y,,,20220608,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome;Nephrolithiasis;Osteomalacia,209293531,OT,,,209293531,1,,,6,YR,209293531,1,HIV infection
20929565,209295651,1,I,,20220525,20220608,20220608,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2022035899,MACLEODS,"Mangal V, Murari T, Gaikwad SN, Kaur K.. Simultaneous Occurrence of Nephrolithiasis, Fanconi Syndrome, and Nephro-osteopathy in a Patient onFirst-line Antiretroviral Therapy - A Case Report. Indian Journal of Nephrology. 2022;32(2):175?178",,,,,Y,,,20220607,,MD,IN,IN,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Acute kidney injury;Fanconi syndrome;Femoral neck fracture;Hydronephrosis;Nephrolithiasis;Nephropathy;Osteomalacia;Pulmonary embolism;Pyelitis;Urinary tract infection,209295651,HO,,,,,,,,,209295651,1,HIV infection
20935663,209356632,2,F,,20220617,20220609,20220627,EXP,,ES-TEVA-2022-ES-2043383,TEVA,,66,YR,E,,Y,,,20220627,,MD,ES,ES,EFAVIRENZ,Drug ineffective for unapproved indication,209356632,DE,,,,,,,,,209356632,1,COVID-19
20938000,209380001,1,I,,20220601,20220609,20220609,EXP,,ZA-AMNEAL PHARMACEUTICALS-2022-AMRX-01621,AMNEAL,,41,YR,,F,Y,,,20220609,,HP,ZA,ZA,EFAVIRENZ,Exposure during pregnancy;Premature delivery,209380001,OT,,,209380001,1,,,5,DAY,209380001,1,Echinococciasis
20940247,209402471,1,I,20120101,20180805,20220609,20220609,EXP,,GB-TEVA-2018-GB-939324,TEVA,,59,YR,A,F,Y,,,20220609,,CN,GB,GB,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Arthritis;Knee operation,209402471,OT,,,,,,,,,209402471,1,HIV infection
20941866,209418661,1,I,,20220527,20220610,20220610,EXP,,UG-AUROBINDO-AUR-APL-2022-020360,AUROBINDO,,37,YR,,F,Y,,,20220610,,HP,UG,UG,"EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE",Abortion spontaneous;Maternal exposure during pregnancy,209418661,OT,,,209418661,1,20210106,20210105,958,DAY,209418661,1,HIV infection
20942966,209429661,1,I,,20220531,20220610,20220610,EXP,,CA-TEVA-2022-CA-2043060,TEVA,,52,YR,A,M,Y,,,20220610,,HP,CA,CA,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,209429661,OT,,,,,,,,,209429661,1,HIV infection
20945024,209450241,1,I,,20220531,20220610,20220610,EXP,,CA-ROCHE-3109610,ROCHE,,54,YR,,M,Y,,,20220610,,HP,CA,,SUSTIVA,Depression;Drug interaction;Intentional product use issue;Loss of personal independence in daily activities;Prescribed overdose,209450241,DE,,,,,,,,,209450241,1,Product used for unknown indication
20946959,209469591,1,I,,20220531,20220610,20220610,EXP,,CA-ROCHE-3109643,ROCHE,,54,YR,,M,Y,,,20220610,,HP,CA,,SUSTIVA,Depression;Drug interaction,209469591,OT,,,,,,,,,209469591,1,HIV infection
20947752,209477522,2,F,20210421,20220608,20220611,20220621,EXP,,ZA-MACLEODS PHARMA UK LTD-MAC2022035919,MACLEODS,,,,,,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion induced;Maternal exposure during pregnancy,209477522,OT,,,209477522,1,20180711,,,,209477522,1,HIV infection
20949197,209491972,2,F,20200101,20220606,20220613,20220616,EXP,,PT-JNJFOC-20220621625,JOHNSON AND JOHNSON,,73,YR,E,F,Y,,,20220617,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209491972,OT,,,209491972,1,2018,2018,,,209491972,1,HIV infection
20950243,209502431,1,I,,20220601,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03698,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug interaction;Drug resistance,209502431,OT,,,,,,,,,209502431,1,HIV infection CDC category C
20950246,209502461,1,I,,20220601,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03695,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209502461,OT,,,,,,,,,209502461,1,HIV infection CDC category C
20950372,209503721,1,I,,20220606,20220613,20220613,EXP,,FR-GILEAD-2022-0584949,GILEAD,"Laparra A, Lerolle N, Gerin M, Cheret A, De CN, Gallien S, Pourcher V, Lanternier F, Bourgarit A, Goujard C. Tumor necrosis factor-alpha inhibitors for extended or severe neurological immune reconstitution inflammatory syndrome in HIV-infected patients. AIDS.. 2021;35:995-997. doi:10.1097/QAD.0000000000002823",37,YR,A,M,Y,,,20220613,,HP,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome,209503721,OT,,,,,,,,,209503721,1,HIV infection
20950790,209507901,1,I,,20220601,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03694,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209507901,OT,,,,,,,,,209507901,1,HIV infection CDC category C
20950791,209507911,1,I,,20220601,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03700,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209507911,OT,,,,,,,,,209507911,1,HIV infection CDC category C
20950793,209507931,1,I,,20220601,20220613,20220613,EXP,,MW-CIPLA LTD.-2022MW03697,CIPLA,"Van Oosterhout JJ, Chipungu C, Nkhoma L, Kanise H, Hosseinipour MC, Sagno JB et al.. Dolutegravir Resistance in Malawi^s National HIV Treatment Program. Open Forum Infectious Diseases. 2022;1 to 5",,,,,Y,,,20220613,,HP,MW,MW,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Adverse drug reaction;Drug resistance,209507931,OT,,,,,,,,,209507931,1,HIV infection CDC category C
20951752,209517521,1,I,,20220603,20220613,20220613,EXP,,CA-ROCHE-3111593,ROCHE,,52,YR,,M,Y,,,20220613,,HP,CA,,EFAVIRENZ;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,209517521,OT,,,,,,,,,209517521,1,HIV infection
20952372,209523722,2,F,,20220609,20220613,20220617,EXP,,DK-MYLANLABS-2022M1043471,MYLAN,"Gulden T, Yahyavi SK, Lodding IP, Jensen J-EB, Blomberg Jensen M. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report.. Bone Reports. 2021;101119",67,YR,,M,Y,,,20220617,,HP,DK,DK,EFAVIRENZ,Acute kidney injury;Dehydration;Diarrhoea;Gait disturbance;Hypocalcaemia;Myalgia;Nausea;Off label use;Vomiting,209523722,HO,,,,,,,,,209523722,1,HIV infection
20954014,209540141,1,I,20200101,20220531,20220614,20220614,EXP,,PT-AUROBINDO-AUR-APL-2022-021508,AUROBINDO,,73,YR,,F,Y,,,20220614,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209540141,OT,,,209540141,1,2013,2014,,,209540141,1,HIV infection
20955561,209555611,1,I,,20220601,20220614,20220614,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-2022-054245,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20220614,,HP,GB,GB,EFAVIRENZ,Feeling abnormal;Life expectancy shortened;Lung cancer metastatic;Malaise;Metastases to central nervous system,209555611,HO,,,,,,,,,209555611,1,Product used for unknown indication
20959265,209592651,1,I,20200101,20220608,20220614,20220614,EXP,,PT-MYLANLABS-2022M1044308,MYLAN,,73,YR,,F,Y,,,20220614,,MD,PT,PT,EFAVIRENZ,Acute myocardial infarction;Endometrial sarcoma;Headache;Metastases to lymph nodes;Monoclonal gammopathy;Nausea;Renal impairment;Vomiting,209592651,OT,,,209592651,1,2013,2014,,,209592651,1,HIV infection
20966864,209668641,1,I,,20220609,20220616,20220616,EXP,,DK-STRIDES ARCOLAB LIMITED-2022SP007262,STRIDES,"Gulden T, Yahyavi SK, Lodding IP, Jensen J-EB, Blomberg Jensen M.. Severe hypocalcemia due to hypoparathyroidism associated with HIV: A case report.. Bone-Rep.. 2021",67,YR,,M,Y,,,20220616,,HP,DK,DK,EFAVIRENZ,Acute kidney injury;Dehydration;Diarrhoea;Gait disturbance;Hypocalcaemia;Myalgia;Nausea;Vomiting,209668641,HO,,,,,,,,,209668641,1,HIV infection
20968050,209680501,1,I,,20220613,20220616,20220616,EXP,,PHHY2017GB177929,NOVARTIS,,85,YR,,M,Y,,,20220616,,MD,GB,GB,EFAVIRENZ,Drug interaction;Renal impairment,209680501,OT,,,,,,,,,209680501,1,Cardiovascular event prophylaxis
20972674,209726741,1,I,20101201,20220602,20220617,20220617,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-2022-052226,BRISTOL MYERS SQUIBB,,,,A,F,Y,,,20220617,,MD,PT,PT,EFAVIRENZ,Drug ineffective;Maternal exposure during pregnancy;Renal impairment;Treatment noncompliance;Viral load increased,209726741,OT,,,209726741,1,200905,201012,19,MON,209726741,1,HIV infection
20973607,209736071,1,I,20210101,20220608,20220617,20220617,EXP,,AT-GILEAD-2022-0585511,GILEAD,,43,YR,A,M,Y,,,20220617,,MD,AT,AT,EFAVIRENZ,Drug resistance;Neoplasm malignant,209736071,OT,,,209736071,1,2017,2017,2,MON,209736071,1,Product used for unknown indication
20975946,209759461,1,I,,20220608,20220617,20220617,EXP,,FR-SAMSUNG BIOEPIS-SB-2022-14242,SAMSUNG BIOEPIS,"Laparra A, Lerolle N, Gerin M, Cheret A, Castro N, Gallien S, Pourcher V, Lanternie F, Bourgarit A, Goujard C. Tumor necrosis factor-alpha inhibitors for extended or severe neurological immune reconstitution inflammatory syndrome in HIV-infected patients. AIDS. 2021;35(6):995-1001. doi:10.1097/QAD.0000000000002823",37,YR,A,M,Y,,,20220617,,HP,FR,FR,EFAVIRENZ,Immune reconstitution inflammatory syndrome associated tuberculosis;Off label use,209759461,OT,,,209759461,1,,,16,DAY,209759461,1,Immune reconstitution inflammatory syndrome associated tuberculosis
20983251,209832511,1,I,,20220613,20220620,20220620,EXP,,ZA-GILEAD-2022-0586430,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,209832511,OT,,,,,,,,,209832511,1,HIV infection
20983263,209832631,1,I,,20220613,20220620,20220620,EXP,,ZA-GILEAD-2022-0586429,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Maternal exposure during pregnancy;Stillbirth,209832631,OT,,,,,,,,,209832631,1,HIV infection
20983271,209832711,1,I,,20220613,20220620,20220620,EXP,,ZA-GILEAD-2022-0586431,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832711,OT,,,,,,,,,209832711,1,HIV infection
20983273,209832731,1,I,,20220613,20220620,20220620,EXP,,ZA-GILEAD-2022-0586428,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832731,OT,,,,,,,,,209832731,1,HIV infection
20983274,209832741,1,I,,20220613,20220620,20220620,EXP,,ZA-GILEAD-2022-0586427,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832741,OT,,,,,,,,,209832741,1,HIV infection
20983277,209832771,1,I,,20220613,20220620,20220620,EXP,,ZA-GILEAD-2022-0586407,GILEAD,"Fairlie L., Brummel S., Ziemba L., Coletti A., Chinula L., Shapiro R.L., Stringer J., Browning R., Chakhtoura N., Mmbaga B.T., Mhembere T.P., Omoz-Oarhe A., Naggadya B., Naidoo M., Lockman S. ADVERSE OUTCOMES in SUBSEQUENT PREGNANCIES in the IMPAACT 2010 TRIAL. Topics in Antiviral Medicine. 2022;30(1 SUPPL):269",,,,F,Y,,,20220620,,HP,ZA,ZA,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,209832771,OT,,,,,,,,,209832771,1,HIV infection
20986261,209862611,1,I,,20220608,20220621,20220621,EXP,,CN-BRISTOL-MYERS SQUIBB COMPANY-2022-055712,BRISTOL MYERS SQUIBB,Acquired immunodeficiency syndrome-related acute longitudinal myelitis involving the entire spinal cord. Neurological Sciences. 2022; 43: 4045-48. 10.1007/s10072-022-06034-7,45,YR,A,M,Y,,,20220621,,HP,CN,CN,EFAVIRENZ,Drug eruption;Hepatic function abnormal,209862611,HO,,,209862611,1,,2022,,,209862611,1,Acquired immunodeficiency syndrome
20993425,209934251,1,I,,20220613,20220622,20220622,EXP,,CA-JNJFOC-20220629261,JOHNSON AND JOHNSON,,54,YR,A,M,Y,,,20220622,,HP,CA,CA,SUSTIVA,Anxiety;Depression suicidal;Depressive symptom;Paranoia;Psychiatric decompensation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,209934251,HO,,,,,,,,,209934251,1,Depression
20994260,209942601,1,I,,20220613,20220622,20220622,EXP,,UG-MYLANLABS-2022M1046767,MYLAN,"Nakiyingi L, Baluku JB, Ssengooba W, Namiiro SM, Buyego P, Kimuli I, et al. Recurrent pneumothorax in a human immunodeficiency virus-positive patient with multidrug-resistant tuberculosis: a rare case of bronchopleural fistula: a case report. J-Med-Case-Rep 2022;16:No. 1.",39,YR,,M,Y,,,20220622,,HP,UG,UG,EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Drug resistance,209942601,HO,,,209942601,1,,,8,MON,209942601,1,Pulmonary tuberculosis
20999301,209993011,1,I,,20220620,20220623,20220623,EXP,,CA-ROCHE-3122758,ROCHE,,54,YR,,M,Y,,,20220623,,HP,CA,,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,209993011,DE,,,,,,,,,209993011,1,Bipolar disorder
20999389,209993891,1,I,,20220617,20220623,20220623,EXP,,JP-GLAXOSMITHKLINE-JP2022JPN094266,GLAXOSMITHKLINE,,,,,,Y,,,20220623,,MD,JP,JP,EFAVIRENZ,Anaemia;Diarrhoea;Malaise;Off label use;Palpitations;Pathogen resistance;Prescribed underdose;Product use issue;Renal cancer;Virologic failure,209993891,OT,,,,,,,,,209993891,1,HIV infection
20999390,209993901,1,I,,20220617,20220623,20220623,EXP,,JP-VIIV HEALTHCARE LIMITED-JP2022JPN094266,VIIV,,,,,,Y,,,20220623,,MD,JP,JP,EFAVIRENZ,Anaemia;Diarrhoea;Malaise;Off label use;Palpitations;Pathogen resistance;Prescribed underdose;Product use issue;Renal cancer;Virologic failure,209993901,OT,,,,,,,,,209993901,1,HIV infection
21000351,210003511,1,I,,20220616,20220623,20220623,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2022GSK093790,VIIV,"John MT, Venter M, Vaughan J, Black M, Prince D, Luke AM et al. Multiple opportunistic infections (pulmonary tuberculosis, Mycobacterium avium complex and parvovirus B19) in a single patient. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20220623,,HP,ZA,ZA,EFAVIRENZ,Drug resistance;Pathogen resistance,210003511,OT,,,210003511,1,2019,2020,3,DAY,210003511,1,HIV infection
21000353,210003531,1,I,,20220616,20220623,20220623,EXP,,ZA-GLAXOSMITHKLINE-ZA2022GSK093790,GLAXOSMITHKLINE,"John MT, Venter M, Vaughan J, Black M, Prince D, Luke AM et al. Multiple opportunistic infections (pulmonary tuberculosis, Mycobacterium avium complex and parvovirus B19) in a single patient. Southern African Journal of HIV Medicine. 2022;23 (1)",,,,,Y,,,20220623,,HP,ZA,ZA,EFAVIRENZ,Drug resistance;Pathogen resistance,210003531,OT,,,210003531,1,2019,2020,3,DAY,210003531,1,HIV infection
21002372,210023721,1,I,,20220622,20220624,20220624,EXP,,US-GILEAD-2022-0587028,GILEAD,,,,E,M,Y,,,20220624,,CN,US,US,EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL FUMARATE,Cognitive disorder,210023721,OT,,,,,,,,,210023721,1,HIV infection
21004836,210048361,1,I,,20220620,20220624,20220624,EXP,,CA-ROCHE-3122588,ROCHE,,54,YR,,M,Y,,,20220624,,HP,CA,,SUSTIVA,Depression;Drug interaction,210048361,OT,,,,,,,,,210048361,1,Product used for unknown indication
21004856,210048561,1,I,,20220621,20220624,20220624,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2022GSK096493,VIIV,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Current Drug Safety. 2022;17 (1):40-46",,,,,Y,,,20220624,,MD,IN,IN,EFAVIRENZ,Death;SJS-TEN overlap,210048561,DE,,,210048561,1,,,30,DAY,210048561,1,Acquired immunodeficiency syndrome
21004858,210048581,1,I,,20220621,20220624,20220624,EXP,,IN-GLAXOSMITHKLINE-IN2022GSK096493,GLAXOSMITHKLINE,"Sivagourounadin K, Rajendran P, Selvarajan S, Ganesapandian M. Agreement Among Different Scales for Causality Assessment in Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Current Drug Safety. 2022;17 (1):40-46",,,,,Y,,,20220624,,MD,IN,IN,EFAVIRENZ,Death;SJS-TEN overlap,210048581,DE,,,210048581,1,,,30,DAY,210048581,1,Acquired immunodeficiency syndrome
21008812,210088121,1,I,20220617,20220621,20220627,20220627,EXP,,CO-BAXTER-2022BAX013175,BAXTER,,53,YR,,M,Y,,,20220627,,HP,CO,CO,EFAVIRENZ,Death,210088121,DE,,,210088121,1,20211129,20220617,201,DAY,210088121,1,Peritoneal dialysis
21012105,210121051,1,I,20210101,20220622,20220627,20220627,EXP,,AT-MYLANLABS-2022M1047984,MYLAN,,43,YR,,M,Y,,,20220627,,MD,AT,AT,EFAVIRENZ,Drug resistance;Neoplasm malignant,210121051,OT,,,210121051,3,2017,2017,2,MON,210121051,1,Product used for unknown indication
21017702,210177021,1,I,,20220622,20220628,20220628,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2022GSK098175,VIIV,,,,,,Y,,,20220628,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,210177021,DE,,,,,,,,,210177021,1,Bipolar disorder
21017703,210177031,1,I,,20220622,20220628,20220628,EXP,,CA-GLAXOSMITHKLINE-CA2022GSK098175,GLAXOSMITHKLINE,,,,,,Y,,,20220628,,HP,CA,CA,EFAVIRENZ,Depression;Drug interaction;Incorrect route of product administration;Loss of personal independence in daily activities;Product use in unapproved indication,210177031,DE,,,,,,,,,210177031,1,Bipolar disorder
21020997,210209971,1,I,20120101,20220617,20220629,20220629,EXP,,GB-AUROBINDO-AUR-APL-2022-023415,AUROBINDO,,59,YR,,F,Y,,,20220629,,CN,GB,GB,EFAVIRENZ,Arthritis;Knee operation,210209971,OT,,,,,,,,,210209971,1,HIV infection
21023783,210237831,1,I,,20220622,20220629,20220629,EXP,,NA-VIIV HEALTHCARE LIMITED-NA2022GSK097227,VIIV,"Kakubu MAM, Bikinesi T, Liswaniso ES, Katoto P DMC. A case of undisclosed prior exposure to antiretroviral therapy (ART) and early virologic failure that improved on a pre-emptive third-line ART regimen. GERMS. 2022;12 (1):102-106",,,,,Y,,,20220629,,MD,,,EFAVIRENZ,Drug resistance;Immunosuppression;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure;Weight decreased,210237831,OT,,,210237831,1,201903,,,,210237831,1,HIV infection WHO clinical stage I
21023785,210237851,1,I,,20220622,20220629,20220629,EXP,,NA-GLAXOSMITHKLINE-NA2022GSK097227,GLAXOSMITHKLINE,"Kakubu MAM, Bikinesi T, Liswaniso ES, Katoto P DMC. A case of undisclosed prior exposure to antiretroviral therapy (ART) and early virologic failure that improved on a pre-emptive third-line ART regimen. GERMS. 2022;12 (1):102-106",,,,,Y,,,20220629,,MD,,,EFAVIRENZ,Drug resistance;Immunosuppression;Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure;Weight decreased,210237851,OT,,,210237851,1,201903,,,,210237851,1,HIV infection WHO clinical stage I
6049025,604902522,22,F,20060216,20220428,20060519,20220511,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-13375589,BRISTOL MYERS SQUIBB,,25,YR,A,F,Y,56,KG,20220512,,MD,FR,FR,SUSTIVA,Abortion induced;Folate deficiency;Insomnia;Maternal exposure during pregnancy;Vertigo,604902522,HO,,,604902522,1,20050523,20050908,109,DAY,604902522,1,HIV infection
6753908,675390815,15,F,20060602,20220517,20080911,20220527,EXP,,CA-MERCK-0809CAN00002,MERCK,"Harris M, Larsen G, Montaner JSG. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS. 2008;22 (14):1890-2",44,YR,,M,Y,,,20220527,,MD,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Depressive symptom;Drug interaction;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychomotor skills impaired;Psychotic disorder;Suicidal ideation;Tearfulness,675390815,HO,,,675390815,1,20070626,20070626,355,DAY,675390815,1,HIV infection
7057071,70570715,5,F,,20220530,20090722,20220609,EXP,,CA-JNJFOC-20090704890,JOHNSON AND JOHNSON,,52,YR,A,M,Y,,,20220609,,MD,CA,CA,EFAVIRENZ,Progressive external ophthalmoplegia,70570715,OT,,,70570715,3,200802,,106,MON,70570715,1,HIV infection
8260766,826076615,15,F,20060101,20220428,20111123,20220512,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-15921299,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20220512,,HP,FR,FR,SUSTIVA,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,826076615,CA,,,826076615,1,20050523,20050908,109,DAY,826076615,1,Product used for unknown indication
8879908,88799086,6,F,20110918,20220419,20121031,20220425,EXP,,JP-GILEAD-2012-0063774,GILEAD,,30,YR,A,M,Y,,,20220425,,MD,JP,JP,EFAVIRENZ,Gastritis;Gastrooesophageal reflux disease;Intentional overdose;Nicotine dependence;Seasonal allergy;Suicide attempt,88799086,LT,,,88799086,1,20110805,20110918,44,DAY,88799086,1,HIV infection
